Merops Switch to
Inhibitors

Peptidase

Family Clan SEARCHES BLAST
MEROPS SUBMISSIONS

Other
information

Literature for peptidase S01.216: coagulation factor Xa

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

(Topics flags: S Structure, A Assay, T Target, K Knockout, P Specificity, E Expression, V Review, M Mutation, I Inhibitor, U Therapeutic. To select only the references relevant to a single topic, click the link above. See explanation.)

    2025
  1. Bozhko,A.A. and Panteleev,M.A.
    A mathematical model for activated platelet-dependent activation of coagulation factor X by factor IXa
    Comput Biol Med192, 110263-110263. PubMed  Europe PubMed DOI
  2. Iglay,K., Aldridge,M.L., Calcinai,M., Wolford,E. and Ashrani,A.A.
    The global epidemiology of acquired factor X deficiency
    Hematology30, 2476254-2476254. PubMed  Europe PubMed DOI  V
  3. Mishima,Y., Okada,H., Butt,A.L., Stewart,K.E., Mazzeffi,M.A. and Tanaka,K.A.
    In vitro procoagulant effects of Gla-domainless factor Xa in factor XI-deficient and factor IX-deficient plasma
    Thromb Res247, 109286-109286. PubMed  Europe PubMed DOI
    4. 2024
  4. Al-Horani,R.A.
    Revisiting the effect of cholesteryl sulfate on clotting and fibrinolysis: Inhibition of human thrombin and other human blood proteases
    Heliyon10, e28017-e28017. PubMed  Europe PubMed DOI  I
  5. Oda,A., Takeyama,M., Kitazawa,T. and Nogami,K.
    The emicizumab-bridged ternary complex with activated factor IX and factor X evaluated by fluorescence resonance energy transfer
    Thromb Res237, 108-111. PubMed  Europe PubMed DOI
  6. Santiago,F., Kaur,A., Bride,S., Monroe,D., Leiderman,K. and Sindi,S.
    A new look at TFPI inhibition of factor X activation
    PLoS Comput Biol20, e1012509-e1012509. PubMed  Europe PubMed DOI
  7. Stojanovski,B.M., Mohammed,B.M. and Di Cera,E.
    The Prothrombin-Prothrombinase Interaction
    Subcell Biochem104, 409-423. PubMed  Europe PubMed DOI  V
  8. Zhu,B., Lane,M.D., Baller,J.A., Jagtap,P.D., Griffin,T.J. and Seelig,B.
    Comprehensive protease specificity profiling
    bioRxiv PubMed  Europe PubMed DOI
    9. 2023
  9. Dong,W., Wang,J., Tian,L., Zhang,J., Settles,E.W., Qin,C., Steinken-Kollath,D.R., Itogawa,A.N., Celona,K.R., Yi,J., Bryant,M., Mead,H., Jaramillo,S.A., Lu,H., Li,A., Zumwalt,R.E., Dadwal,S., Feng,P., Yuan,W., Whelan,S.P.J., Keim,P.S., Barker,B.M., Caligiuri,M.A. and Yu,J.
    Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection
    Nat Commun14, 1936-1936. PubMed  Europe PubMed DOI
  10. Gackowski,M., Madriwala,B., Studzinska,R. and Koba,M.
    Novel Isosteviol-Based FXa Inhibitors: Molecular Modeling, In Silico Design and Docking Simulation
    Molecules28, PubMed  Europe PubMed DOI
  11. Lloyd,J. and Feldman,P.
    Preclinical development and characterization of a human plasma-derived high-purity factor X concentrate for therapeutic use
    Haemophilia29, 1394-1409. PubMed  Europe PubMed DOI
  12. Novichikhina,N.P., Shestakov,A.S., Medvedeva,S.M., Lagutina,A.M., Krysin,M.Y., Podoplelova,N.A., Panteleev,M.A., Ilin,I.S., Sulimov,A.V., Tashchilova,A.S., Sulimov,V.B., Geronikaki,A. and Shikhaliev,K.S.
    New Hybrid Tetrahydropyrrolo[3,2,1-ij]quinolin-1-ylidene-2-thioxothiazolidin-4-ones as New Inhibitors of Factor Xa and Factor XIa: Design, Synthesis, and In Silico and Experimental Evaluation
    Molecules28, PubMed  Europe PubMed DOI  I
  13. Wagner,N., Shayakhmetov,D.M. and Stewart,P.L.
    Structural Model for Factor X Inhibition of IgM and Complement-Mediated Neutralization of Adenovirus
    Viruses15, PubMed  Europe PubMed DOI
  14. Wang,H., Poe,A., Martinez Yus,M., Pak,L., Nandakumar,K. and Santhanam,L.
    Lysyl oxidase-like 2 processing by factor Xa modulates its activity and substrate preference
    Commun Biol6, 375-375. PubMed  Europe PubMed DOI
  15. Wu,S., Wang,T., Li,J., Zhang,Z., Li,C., Xiao,S., He,J., Wang,X., Hu,Z., Wang,X., Zheng,S., Liang,X., Chen,G., Li,Y., Li,X., Zhan,Y., Zou,Q., Jiang,H., Zheng,Q., Ban,L., Liu,H. and Fang,Y.
    First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa
    Expert Opin Investig Drugs32, 1085-1094. PubMed  Europe PubMed DOI  I
  16. Yoon,H.J., Kundu,S. and Wu,S.
    Molecular Dynamics Simulation Study of the Selective Inhibition of Coagulation Factor IXa over Factor Xa
    Molecules28, PubMed  Europe PubMed DOI
  17. Zhang,Q., Zhang,Z., Chen,W., Zheng,H., Si,D. and Zhang,W.
    Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-beta1 signaling pathways
    PeerJ11, e16097-e16097. PubMed  Europe PubMed DOI  I
    18. 2022
  18. Fernandez-Bachiller,M.I., Hwang,S., Schembri,M.E., Lindemann,P., Guberman,M., Herziger,S., Specker,E., Matter,H., Will,D.W., Czech,J., Wagner,M., Bauer,A., Schreuder,H., Ritter,K., Urmann,M., Wehner,V., Sun,H. and Nazare,M.
    Probing Factor Xa Protein-Ligand Interactions: Accurate Free Energy Calculations and Experimental Validations of Two Series of High-Affinity Ligands
    J Med Chem65, 13013-13028. PubMed  Europe PubMed DOI
  19. Gackowski,M., Szewczyk-Golec,K., Madra-Gackowska,K., Pluskota,R. and Koba,M.
    Quantitative Structure-Activity Relationship Analysis of Isosteviol-Related Compounds as Activated Coagulation Factor X (FXa) Inhibitors
    Nutrients14, PubMed  Europe PubMed DOI
  20. Modrzycka,S., Kolt,S., Polderdijk,S.G.I., Adams,T.E., Potoczek,S., Huntington,J.A., Kasperkiewicz,P. and Drag,M.
    Parallel imaging of coagulation pathway proteases activated protein C, thrombin, and factor Xa in human plasma
    Chem Sci13, 6813-6829. PubMed  Europe PubMed DOI
  21. Payne,J., Batsuli,G., Leavitt,A.D., Mathias,M. and McGuinn,C.E.
    A review of the pharmacokinetics, efficacy and safety of high-purity factor X for the prophylactic treatment of hereditary factor X deficiency
    Haemophilia28, 523-531. PubMed  Europe PubMed DOI
  22. Ruben,E.A., Summers,B., Rau,M.J., Fitzpatrick,J.A.J. and Di Cera,E.
    Cryo-EM structure of the prothrombin-prothrombinase complex
    Blood139, 3463-3473. PubMed  Europe PubMed DOI
  23. Schroer,K., Alshawabkeh,M., Schellhorn,S., Bronder,K., Zhang,W. and Ehrhardt,A.
    Influence of Heparan Sulfate Proteoglycans and Factor X on species D Human Adenovirus Uptake and Transduction
    Viruses15, PubMed  Europe PubMed DOI
  24. Zekri-Nechar,K., Zamorano-Leon,J.J., Reche,C., Giner,M., Lopez-de-Andres,A., Jimenez-Garcia,R., Lopez-Farre,A.J. and Martinez-Martinez,C.H.
    Spike Protein Subunits of SARS-CoV-2 Alter Mitochondrial Metabolism in Human Pulmonary Microvascular Endothelial Cells: Involvement of Factor Xa
    Dis Markers2022, 1118195-1118195. PubMed  Europe PubMed DOI
  25. Zhang,Z.L., Chen,C., Qu,S.Y., Ding,Q. and Xu,Q.
    Unexpected Dynamic Binding May Rescue the Binding Affinity of Rivaroxaban in a Mutant of Coagulation Factor X
    Front Mol Biosci9, 877170-877170. PubMed  Europe PubMed DOI  I
    26. 2021
  26. Ebert,M., Raquet,E., Schweisgut,S., Schmidt,P.M. and Weimer,T.
    Identification of a modified coagulation factor X with enhanced activation properties as potential hemostatic agent
    Blood Cells Mol Dis89, 102570-102570. PubMed  Europe PubMed DOI
  27. Fischer,A., Sellner,M., Mitusinska,K., Bzowka,M., Lill,M.A., Gora,A. and Smiesko,M.
    Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2
    Int J Mol Sci22, PubMed  Europe PubMed DOI
  28. Ichinose,A., Osaki,T. and Souri,M.
    Autoimmune Coagulation Factor X Deficiency as a Rare Acquired Hemorrhagic Disorder: A Literature Review
    Thromb Haemost PubMed  Europe PubMed DOI
  29. Jackson,C.M.
    Structure and function of factor X: properties, activation, and activity in prothrombinase. A retrospective in a historical context
    J Thromb Thrombolysis PubMed  Europe PubMed DOI
  30. Kundu,S. and Wu,S.
    A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa
    Molecules26, PubMed  Europe PubMed DOI
  31. Paul,D. and Morrissey,J.H.
    Stoichiometric analysis reveals a unique phosphatidylserine binding site in coagulation factor X
    J Thromb Haemost PubMed  Europe PubMed DOI
  32. Ruf,W.
    Roles of factor Xa beyond coagulation
    J Thromb Thrombolysis PubMed  Europe PubMed DOI
    33. 2020
  33. Al-Horani,R.A.
    Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections
    Am J Cardiovasc Drugs20, 525-533. PubMed  Europe PubMed DOI  V
  34. Basavaraj,M.G. and Krishnaswamy,S.
    Exosite binding drives substrate affinity for the activation of coagulation factor X by the intrinsic Xase complex
    J Biol Chem PubMed  Europe PubMed DOI
  35. de Laat-Kremers,R.M.W., Yan,Q., Ninivaggi,M., de Maat,M. and de Laat,B.
    Deciphering the coagulation profile through the dynamics of thrombin activity
    Sci Rep10, 12544-12544. PubMed  Europe PubMed DOI
  36. Dorgalaleh,A., Baghaipour,M.R., Tabibian,S., Ghazizadeh,F., Dabbagh,A., Bahoush,G., Jazebi,M., Bahraini,M., Fazeli,A., Baghaipour,N. and Yousefi,F.
    Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection
    Int J Lab Hematol PubMed  Europe PubMed DOI
  37. Frydman,G.H., Streiff,M.B., Connors,J.M. and Piazza,G.
    The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents
    TH Open4, e288-e288. PubMed  Europe PubMed DOI  V
  38. Papadaki,S., Sidiropoulou,S., Moschonas,I.C. and Tselepis,A.D.
    Factor Xa and thrombin induce endothelial progenitor cell activation. The effect of direct oral anticoagulants
    Platelets1-8. PubMed  Europe PubMed DOI  I
  39. Ruf,W. and Graf,C.
    Coagulation signaling and cancer immunotherapy
    Thromb Res191 Suppl 1, S106-S106. PubMed  Europe PubMed DOI
  40. Shima,M.
    Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia
    Res Pract Thromb Haemost4, 446-454. PubMed  Europe PubMed DOI
  41. Stallone,G., Pontrelli,P., Rascio,F., Castellano,G., Gesualdo,L. and Grandaliano,G.
    Coagulation and Fibrinolysis in Kidney Graft Rejection
    Front Immunol11, 1807-1807. PubMed  Europe PubMed DOI  V
  42. Zhang,X., Chen,K., Wang,G., Zhang,C., Zhao,B., Liu,X., Qin,X. and Yang,L.
    Molecular mechanism of a novel Ser362Asn mutation causing inherited FX deficiency in a Chinese family
    Int J Hematol112, 8-16. PubMed  Europe PubMed DOI  M
  43. Zimowski,K.L., McGuinn,C.E., Abajas,Y.L., Schultz,C.L., Kaicker,S. and Batsuli,G.
    Use of plasma-derived factor X concentrate in neonates and infants with congenital factor X deficiency
    J Thromb Haemost18, 2551-2556. PubMed  Europe PubMed DOI
    44. 2019
  44. Abache,T., Fontayne,A., Grenier,D., Jacque,E., Longue,A., Dezetter,A.S., Souilliart,B., Chevreux,G., Bataille,D., Chtourou,S. and Plantier,J.L.
    A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A
    Haematologica105, 2335-2340. PubMed  Europe PubMed DOI
  45. Ferrarese,M., Pignani,S., Lombardi,S., Balestra,D., Bernardi,F., Pinotti,M. and Branchini,A.
    The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies
    Thromb Res173, 4-11. PubMed  Europe PubMed DOI  E
  46. Ferrarese,M., Baroni,M., Della Valle,P., Spiga,I., Poloniato,A., D'Angelo,A., Pinotti,M., Bernardi,F. and Branchini,A.
    Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition
    Haemophilia25, 685-692. PubMed  Europe PubMed DOI  M
  47. Girard,T.J., Lasky,N.M., Grunz,K. and Broze GJ Jr
    Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A
    J Thromb Haemost17, 149-156. PubMed  Europe PubMed DOI
  48. Girolami,A., de Paoletti,D.N.G., Nenkies,M.L., Ferrari,S. and Guglielmone,H.
    Factor X deficiency due to a compound heterozygosis between a new mutation (Gla72Asp) in exon 2 and an already known one (Gly154Arg) in exon 5: factor X Mar del Plata1)
    Cardiovasc Hematol Disord Drug Targets19, 169-173. PubMed  Europe PubMed DOI  M
  49. Ilin,I., Lipets,E., Sulimov,A., Kutov,D., Shikhaliev,K., Potapov,A., Krysin,M., Zubkov,F., Sapronova,L., Ataullakhanov,F. and Sulimov,V.
    New factor Xa inhibitors based on 1,2,3,4-tetrahydroquinoline developed by molecular modelling
    J Mol Graph Model89, 215-224. PubMed  Europe PubMed DOI  I
  50. Li,F., Chen,C., Qu,S.Y., Zhao,M.Z., Xie,X., Wu,X., Li,L., Wang,X., Ding,Q., Xu,Q., Wei,D.Q. and Wu,W.
    The disulfide bond between Cys22 and Cys27 in the protease domain modulate clotting activity of coagulation factor X
    Thromb Haemost119, 871-881. PubMed  Europe PubMed DOI
  51. Mitchell,M., Gattens,M., Kavakli,K., Liesner,R., Payne,J., Norton,M. and Austin,S.
    Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency
    Blood Coagul Fibrinolysis30, 34-41. PubMed  Europe PubMed DOI  M
  52. Muczynski,V., Verhenne,S., Casari,C., Cherel,G., Panicot-Dubois,L., Gueguen,P., Trossaert,M., Dubois,C., Lenting,P.J., Denis,C.V. and Christophe,O.D.
    A thrombin-activatable factor X variant corrects hemostasis in a mouse model for hemophilia A
    Thromb Haemost119, 1981-1993. PubMed  Europe PubMed DOI  U
  53. Othman,T., Abdelkarim,A., Huynh,K., Uche,A. and Lee,J.
    Inherited moderate factor X deficiency presenting as cardiac tamponade
    Case Rep Hematol2019, 9657516-9657516. PubMed  Europe PubMed DOI  M
  54. Qu,S.Y., Xu,Q., Wu,W., Li,F., Li,C.D., Huang,R., Ding,Q. and Wei,D.Q.
    An unexpected dynamic binding mode between coagulation factor X and rivaroxaban reveals importance of flexibility in drug binding
    Chem Biol Drug Des94, 1664-1671. PubMed  Europe PubMed DOI  I
  55. van Dievoet,M.A., Jacquemin,M., Van Calsteren,K. and Peerlinck,K.
    A rare presentation of homozygous factor X deficiency in a pregnant patient: a case report and review of the literature
    Haemophilia25, e57-e57. PubMed  Europe PubMed DOI  M
    56. 2018
  56. Arita,K., Niimi,H., Yamagishi,N., Ueno,T., Kitajima,I. and Sugiyama,T.
    Factor X heterozygous mutation in a patient with potential risk of bleeding: a case report
    Medicine (Baltimore)97, e10950-e10950. PubMed  Europe PubMed DOI  M
  57. Augustsson,C., Svensson,A., Kjaer,B., Chao,T.Y., Wenjuan,X., Krogh,B.O., Breinholt,J., Clausen,J.T., Hilden,I., Petersen,H.H. and Petersen,L.C.
    Factor Xa and VIIa inhibition by tissue factor pathway Inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain
    J Thromb Haemost16, 893-904. PubMed  Europe PubMed DOI
  58. Girolami,A., Cosi,E., Santarossa,C., Ferrari,S., Girolami,B. and Lombardi,A.M.
    Factor X Friuli coagulation disorder: almost 50 years later
    Clin Appl Thromb Hemost24, 33-40. PubMed  Europe PubMed DOI  M
  59. Gunaratne,R., Kumar,S., Frederiksen,J.W., Stayrook,S., Lohrmann,J.L., Perry,K., Bompiani,K.M., Chabata,C.V., Thalji,N.K., Ho,M.D., Arepally,G., Camire,R.M., Krishnaswamy,S. and Sullenger,B.A.
    Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass
    Nat Biotechnol36, 606-613. PubMed  Europe PubMed DOI
  60. Horinaka,S., Sugawara,R., Yonezawa,Y. and Ishimitsu,T.
    Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation
    Br J Clin Pharmacol84, 79-87. PubMed  Europe PubMed DOI  I
  61. Hu,X., Xiao,Y., Yu,C., Zuo,Y., Yang,W., Wang,X., Gu,B. and Li,J.
    Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding
    Eur J Pharmacol825, 85-91. PubMed  Europe PubMed DOI  I
  62. Jourdi,G., Gouin-Thibault,I., Siguret,V., Gandrille,S., Gaussem,P. and Le Bonniec,B.
    FXa-alpha2-Macroglobulin complex neutralizes direct oral anticoagulants targeting FXa in vitro and in vivo
    Thromb Haemost118, 1535-1544. PubMed  Europe PubMed DOI  U
  63. Kanade,G.D., Pingale,K.D. and Karpe,Y.A.
    Activities of thrombin and factor Xa are essential for replication of hepatitis E virus and are possibly implicated in the ORF1 polyprotein processing
    J Virol92, e01853-17-e01853-17. PubMed  Europe PubMed DOI
  64. Lu,G., Pine,P., Leeds,J.M., DeGuzman,F., Pratikhya,P., Lin,J., Malinowski,J., Hollenbach,S.J., Curnutte,J.T. and Conley,P.B.
    Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model
    PLoS ONE13, e0195122-e0195122. PubMed  Europe PubMed DOI  I
  65. Ramesh,K., Lama,D., Tan,K.W., Nguyen,V.S., Chew,F.T., Verma,C.S. and Mok,Y.K.
    Homologous lympho-epithelial Kazal-type inhibitor domains delay blood coagulation by inhibiting factor X and XI with differential specificity
    Structure26, 1178-1186. PubMed  Europe PubMed DOI
  66. Shinozawa,E., Nakayama,M. and Imura,Y.
    TAK-442, a direct factor Xa inhibitor, inhibits monocyte chemoattractant protein 1 production in endothelial cells via involvement of protease-activated receptor 1
    Front Pharmacol9, 1431-1431. PubMed  Europe PubMed DOI  I
    67. 2017
  67. Hack,K., Renzi,F., Hess,E., Lauber,F., Douxfils,J., Dogne,J.M. and Cornelis,G.R.
    Inactivation of human coagulation factor X by a protease of the pathogen Capnocytophaga canimorsus
    J Thromb Haemost15, 487-499. PubMed  Europe PubMed DOI
  68. Hu,Z., Liu,Y., Huarng,M.C., Menegatti,M., Reyon,D., Rost,M.S., Norris,Z.G., Richter,C.E., Stapleton,A.N., Chi,N.C., Peyvandi,F., Joung,J.K. and Shavit,J.A.
    Genome editing of factor X in zebrafish reveals unexpected tolerance of severe defects in the common pathway
    Blood130, 666-676. PubMed  Europe PubMed DOI
  69. Jaegle,M., Steinmetzer,T. and Rademann,J.
    Protein-templated formation of an inhibitor of the blood coagulation factor Xa through a background-free amidation reaction
    Angew Chem Int Ed Engl56, 3718-3722. PubMed  Europe PubMed DOI  I
  70. Kovalenko,T.A., Panteleev,M.A. and Sveshnikova,A.N.
    Substrate delivery mechanism and the role of membrane curvature in factor X activation by extrinsic tenase
    J Theor Biol435, 125-133. PubMed  Europe PubMed DOI
  71. Lagos,C.F., Segovia,G.F., Nunez-Navarro,N., Faundez,M.A. and Zacconi,F.C.
    Novel FXa inhibitor identification through integration of ligand- and structure-based approaches
    Molecules22, PubMed  Europe PubMed DOI  I
  72. Lenting,P.J., Denis,C.V. and Christophe,O.D.
    Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
    Blood130, 2463-2468. PubMed  Europe PubMed DOI
  73. Thalji,N.K. and Camire,R.M.
    Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding
    Curr Opin Hematol24, 453-459. PubMed  Europe PubMed DOI  U
    74. 2016
  74. Arian,D., Harenberg,J. and Kramer,R.
    A chromogenic and fluorogenic peptide substrate for the highly sensitive detection of proteases in biological matrices
    J Med Chem59, 7576-7583. PubMed  Europe PubMed DOI  A
  75. Camire,R.M.
    Bioengineering factor Xa to treat bleeding
    Thromb Res141 Suppl 2, S31-S33. PubMed  Europe PubMed DOI  E  U
  76. Escobar,M.A., Auerswald,G., Austin,S., Huang,J.N., Norton,M. and Millar,C.M.
    Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery
    Haemophilia22, 713-720. PubMed  Europe PubMed DOI  U
  77. Girish,V.M. and Kini,R.M.
    Exactin: a specific inhibitor of factor X activation by extrinsic tenase complex from the venom of Hemachatus haemachatus
    Sci Rep6, 32036-32036. PubMed  Europe PubMed DOI
  78. Girolami,A., Molina,M.A., Galletti,M.L., Ferrari,S., Sambado,L. and Guglielmone,H.
    A family with factor X deficiency from Argentina: a compound heterozygosis because of the combination of a new mutation (Gln138Arg) with an already known one (Glu350Lys)
    Blood Coagul Fibrinolysis27, 732-736. PubMed  Europe PubMed DOI  M
  79. Peraramelli,S., Thomassen,S., Heinzmann,A., Hackeng,T.M., Hartmann,R., Scheiflinger,F., Dockal,M. and Rosing,J.
    Role of exosite binding modulators in the inhibition of FXa by TFPI
    Thromb Haemost115, 580-590. PubMed  Europe PubMed DOI
  80. Pryzdial,E.L., Meixner,S.C., Talbot,K., Eltringham-Smith,L.J., Baylis,J.R., Lee,F.M., Kastrup,C.J. and Sheffield,W.P.
    Thrombolysis by chemically modified coagulation factor Xa
    J Thromb Haemost14, 1844-1854. PubMed  Europe PubMed DOI
  81. Sharma,M., Iyer,J.K., Shih,N., Majumder,M., Mattaparthi,V.S., Mukhopadhyay,R. and Doley,R.
    Daboxin P, a major phospholipase A2 enzyme from the Indian Daboia russelii russelii venom targets factor X and factor Xa for its anticoagulant activity
    PLoS ONE11, e0153770-e0153770. PubMed  Europe PubMed DOI
  82. Sun,N., Chen,Y., Peng,H., Luo,Y. and Zhang,G.
    A novel Ala275Val mutation in factor X gene influences its structural compatibility and impairs intracellular trafficking and coagulant activity
    Thromb Res138, 108-113. PubMed  Europe PubMed DOI  M
    83. 2015
  83. Baroni,M., Pavani,G., Pinotti,M., Branchini,A., Bernardi,F. and Camire,R.M.
    Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation
    Biochim Biophys Acta1854, 1351-1356. PubMed  Europe PubMed DOI
  84. Block,H., Maertens,B., Spriestersbach,A., Kubicek,J. and Schafer,F.
    Proteolytic affinity tag cleavage
    Methods Enzymol559, 71-97. PubMed  Europe PubMed DOI
  85. Branchini,A., Baroni,M., Burini,F., Puzzo,F., Nicolosi,F., Mari,R., Gemmati,D., Bernardi,F. and Pinotti,M.
    The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X
    J Thromb Haemost13, 1468-1474. PubMed  Europe PubMed DOI
  86. Chevreux,G., Tilly,N., Faid,V. and Bihoreau,N.
    Mass spectrometry based analysis of human plasma-derived factor X revealed novel post-translational modifications
    Protein Sci24, 1640-1648. PubMed  Europe PubMed DOI
  87. Corsini,I., Menegatti,M., Cairo,A. and Dani,C.
    Neonatal onset of congenital factor X deficiency: a description of two novel mutations with 6-year follow-up
    Blood Coagul Fibrinolysis26, 679-681. PubMed  Europe PubMed DOI  M
  88. Eyre,T.A., Bignell,P. and Keeling,D.
    Factor X deficiency associated with compound heterozygosity involving a novel missense mutation at codon 38 from Val (GTC) to Leu (CTC) in exon 2
    Blood Coagul Fibrinolysis26, 352-353. PubMed  Europe PubMed DOI  M
  89. Girolami,A., Cosi,E., Sambado,L., Girolami,B. and Randi,M.L.
    Complex history of the discovery and characterization of congenital factor X deficiency
    Semin Thromb Hemost41, 359-365. PubMed  Europe PubMed DOI  V
  90. Ivanciu,L. and Camire,R.M.
    Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity
    Blood126, 94-102. PubMed  Europe PubMed DOI  U
  91. Noguchi,K., Morishima,Y., Takahashi,S., Ishihara,H., Shibano,T. and Murata,M.
    Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban
    Blood Coagul Fibrinolysis26, 117-122. PubMed  Europe PubMed DOI  M  I
  92. Wang,Y., Ma,J., Liu,X., Wang,Y., Wang,H., Wang,L., Ding,Q., Chu,X. and Hou,M.
    A novel factor X gene mutation Val (GTC) 384Ala (GCC) in a Chinese family resulting in congenital factor X deficiency
    Int J Clin Exp Med8, 10095-10098. PubMed  Europe PubMed  M
    93. 2014
  93. Abdel-Azeim,S., Oliva,R., Chermak,E., De Cristofaro,R. and Cavallo,L.
    Molecular dynamics characterization of five pathogenic factor X mutants associated with decreased catalytic activity
    Biochemistry53, 6992-7001. PubMed  Europe PubMed DOI  M
  94. Belviso,B.D., Caliandro,R., de Candia,M., Zaetta,G., Lopopolo,G., Incampo,F., Colucci,M. and Altomare,C.D.
    How a beta-D-glucoside side chain enhances binding affinity to thrombin of inhibitors bearing 2-chlorothiophene as P1 moiety: crystallography, fragment deconstruction study, and evaluation of antithrombotic properties
    J Med Chem57, 8563-8575. PubMed  Europe PubMed DOI  I
  95. Bijak,M., Ponczek,M.B. and Nowak,P.
    Polyphenol compounds belonging to flavonoids inhibit activity of coagulation factor X
    Int J Biol Macromol65, 129-135. PubMed  Europe PubMed DOI  I
  96. Bounameaux,H. and Camm,A.J.
    Edoxaban: an update on the new oral direct factor Xa inhibitor
    Drugs74, 1209-1231. PubMed  Europe PubMed DOI  I
  97. Chikasawa,Y., Shinozawa,K., Amano,K., Ogata,K., Hagiwara,T., Suzuki,T., Inaba,H. and Fukutake,K.
    Factor X M402T: a homozygous missense mutation identified as the cause of cross-reacting material-reduced deficiency
    Int J Hematol100, 345-352. PubMed  Europe PubMed DOI  M
  98. Esmon,C.T.
    Targeting factor Xa and thrombin: impact on coagulation and beyond
    Thromb Haemost111, 625-633. PubMed  Europe PubMed DOI  I
  99. Jiang,L., Wang,Q., Shen,S., Xiao,T. and Li,Y.
    Discovery of glycyrrhetinic acid as an orally active, direct inhibitor of blood coagulation factor Xa
    Thromb Res133, 501-506. PubMed  Europe PubMed DOI  I
  100. Lu,Q., Yang,L., Manithody,C., Wang,X. and Rezaie,A.R.
    Molecular basis of the clotting defect in a bleeding patient missing the Asp-185 codon in the factor X gene
    Thromb Res134, 1103-1109. PubMed  Europe PubMed DOI  M
  101. Menegatti,M., Vangone,A., Palla,R., Milano,G., Cavallo,L., Oliva,R., De Cristofaro,R. and Peyvandi,F.
    A recurrent Gly43Asp substitution in coagulation factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking
    Thromb Res133, 481-487. PubMed  Europe PubMed DOI  M
  102. Mourier,P.A., Guichard,O.Y., Herman,F. and Viskov,C.
    Isolation of a pure octadecasaccharide with antithrombin activity from an ultra-low-molecular-weight heparin
    Anal Biochem453, 7-15. PubMed  Europe PubMed DOI
  103. Nguyen,C.N., Cruz,A., Gilson,M.K. and Kurtzman,T.
    Thermodynamics of water in an enzyme active site: grid-based hydration analysis of coagulation factor Xa
    J Chem Theory Comput10, 2769-2780. PubMed  Europe PubMed DOI
  104. Pomowski,A., Ustok,F.I. and Huntington,J.A.
    Homology model of human prothrombinase based on the crystal structure of pseutarin C
    Biol Chem395, 1233-1241. PubMed  Europe PubMed DOI
  105. Pozzi,N., Chen,Z., Pelc,L.A., Shropshire,D.B. and Di Cera,E.
    The linker connecting the two kringles plays a key role in prothrombin activation
    Proc Natl Acad Sci U S A111, 7630-7635. PubMed  Europe PubMed DOI
  106. Thakur,R., Kumar,A., Bose,B., Panda,D., Saikia,D., Chattopadhyay,P. and Mukherjee,A.K.
    A new peptide (Ruviprase) purified from the venom of Daboia russelii russelii shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor Xa
    Biochimie105, 149-158. PubMed  Europe PubMed DOI  I
    107. 2013
  107. Ding,Q., Shen,Y., Yang,L., Wang,X. and Rezaie,A.R.
    The missense Thr211Pro mutation in the factor X activation peptide of a bleeding patient causes molecular defect in the clotting cascade
    Thromb Haemost110, 53-61. PubMed  Europe PubMed DOI  M
  108. Griffiths,A.E., Wintermute,J., Newell-Caito,J.L. and Fay,P.J.
    Residues flanking scissile bonds in factor VIII modulate rates of cleavage and proteolytic activation catalyzed by factor Xa
    Biochemistry52, 8060-8068. PubMed  Europe PubMed DOI  P
  109. King,C.S., Holley,A.B. and Moores,L.K.
    Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors
    Chest143, 1106-1116. PubMed  Europe PubMed DOI  I
  110. Lu,G., Deguzman,F.R., Hollenbach,S.J., Karbarz,M.J., Abe,K., Lee,G., Luan,P., Hutchaleelaha,A., Inagaki,M., Conley,P.B., Phillips,D.R. and Sinha,U.
    A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
    Nat Med19, 446-451. PubMed  Europe PubMed DOI
  111. Meneyrol,J., Follmann,M., Lassalle,G., Wehner,V., Barre,G., Rousseaux,T., Altenburger,J.M., Petit,F., Bocskei,Z., Schreuder,H., Alet,N., Herault,J.P., Millet,L., Dol,F., Florian,P., Schaeffer,P., Sadoun,F., Klieber,S., Briot,C., Bono,F. and Herbert,J.M.
    5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor
    J Med Chem56, 9441-9456. PubMed  Europe PubMed DOI  I
  112. Talbot,K., Meixner,S.C. and Pryzdial,E.L.
    Proteolytic modulation of factor Xa-antithrombin complex enhances fibrinolysis in plasma
    Biochim Biophys Acta1834, 989-995. PubMed  Europe PubMed DOI
  113. Zhou,J.W., Liang,Q., Chen,Q., Xie,Y., Ding,Q.L., Wang,X.F., Xi,X.D. and Wang,H.L.
    Molecular defects in the factor X gene caused by novel heterozygous mutations IVS5+1G>A and Asp409del
    Haemophilia19, 94-99. PubMed  Europe PubMed DOI  M
    114. 2012
  114. Ahrens,I. and Bode,C.
    New parenteral anticoagulants: focus on factor Xa and thrombin inhibitors
    Curr Drug Discov Technol9, 129-136. PubMed  Europe PubMed  I
  115. Becattini,C., Lignani,A. and Agnelli,G.
    New oral anticoagulants for venous thromboembolism: focus on factor Xa and thrombin inhibitors
    Curr Drug Discov Technol9, 119-128. PubMed  Europe PubMed  I
  116. Brown,M.A., Stenberg,L.M. and Stenflo,J.
    Coagulation factor Xa
    [ISSN:978-0-12-407742-3]3, 2908-2915. DOI
  117. Lopopolo,G., de Candia,M., Panza,L., Romano,M.R., Lograno,M.D., Campagna,F. and Altomare,C.
    beta-D-Glucosyl conjugates of highly potent inhibitors of blood coagulation factor Xa bearing 2-chorothiophene as a P1 motif
    ChemMedChem7, 1669-1677. PubMed  Europe PubMed DOI  I
  118. Marlu,R. and Polack,B.
    Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex
    Haematologica97, 1165-1172. PubMed  Europe PubMed DOI  U
  119. Nakatomi,Y., Tsuji,M., Gokudan,S., Hanada-Dateki,T., Nakashima,T., Miyazaki,H., Hamamoto,T., Nakagaki,T. and Tomokiyo,K.
    Stable complex formation between serine protease inhibitor and zymogen: coagulation factor X cleaves the Arg393-Ser394 bond in a reactive centre loop of antithrombin in the presence of heparin
    J Biochem152, 463-470. PubMed  Europe PubMed DOI  P
  120. Nar,H.
    The role of structural information in the discovery of direct thrombin and factor Xa inhibitors
    Trends Pharmacol Sci33, 279-288. PubMed  Europe PubMed DOI  V  I
  121. Olson,S.T., Swanson,R. and Petitou,M.
    Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa
    Blood119, 2187-2195. PubMed  Europe PubMed DOI  I
  122. Salonen,L.M., Holland,M.C., Kaib,P.S., Haap,W., Benz,J., Mary,J.L., Kuster,O., Schweizer,W.B., Banner,D.W. and Diederich,F.
    Molecular recognition at the active site of factor Xa: cation-pi interactions, stacking on planar peptide surfaces, and replacement of structural water
    Chemistry18, 213-222. PubMed  Europe PubMed DOI
  123. Takeyama,M., Wakabayashi,H. and Fay,P.J.
    Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase
    Biochemistry51, 820-828. PubMed  Europe PubMed DOI
  124. Vanden Hoek,A.L., Talbot,K., Carter,I.S., Vickars,L., Carter,C.J., Jackson,S.C., MacGillivray,R.T. and Pryzdial,E.L.
    Coagulation factor X Arg386 specifically affects activation by the intrinsic pathway: a novel patient mutation
    J Thromb Haemost10, 2613-2615. PubMed  Europe PubMed DOI  M
    125. 2011
  125. Bhunia,S.S., Roy,K.K. and Saxena,A.K.
    Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches
    J Chem Inf Model51, 1966-1985. PubMed  Europe PubMed DOI  I
  126. Bunce,M.W., Toso,R. and Camire,R.M.
    Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro
    Blood117, 290-298. PubMed  Europe PubMed DOI  U
  127. Duffy,M.R., Bradshaw,A.C., Parker,A.L., McVey,J.H. and Baker,A.H.
    A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes
    J Virol85, 10914-10919. PubMed  Europe PubMed DOI
  128. Hirayama,F., Koshio,H., Ishihara,T., Hachiya,S., Sugasawa,K., Koga,Y., Seki,N., Shiraki,R., Shigenaga,T., Iwatsuki,Y., Moritani,Y., Mori,K., Kadokura,T., Kawasaki,T., Matsumoto,Y., Sakamoto,S. and Tsukamoto,S.
    Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a potent and orally available factor Xa inhibitor
    J Med Chem54, 8051-8065. PubMed  Europe PubMed DOI  I
  129. Ivanciu,L., Toso,R., Margaritis,P., Pavani,G., Kim,H., Schlachterman,A., Liu,J.H., Clerin,V., Pittman,D.D., Rose-Miranda,R., Shields,K.M., Erbe,D.V., Tobin,J.F., Arruda,V.R. and Camire,R.M.
    A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia
    Nat Biotechnol29, 1028-1033. PubMed  Europe PubMed DOI
  130. Livnat,T., Shenkman,B., Kenet,G., Tamarin,I., Gillis,S., Varon,D., Iijima,K., Zivelin,A. and Salomon,O.
    Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG - correlation with thrombin generation and thromboelastometry
    Blood Coagul Fibrinolysis22, 673-679. PubMed  Europe PubMed DOI  M
  131. Lopopolo,G., Fiorella,F., de Candia,M., Nicolotti,O., Martel,S., Carrupt,P.A. and Altomare,C.
    Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa
    Eur J Pharm Sci42, 180-191. PubMed  Europe PubMed DOI  I
  132. Schilling,O., dem Keller,U.A. and Overall,C.M.
    Factor Xa subsite mapping by proteome-derived peptide libraries improved using WebPICS, a resource for proteomic identification of cleavage sites
    Biol Chem392, 1031-1037. PubMed  Europe PubMed DOI  P
  133. Siigur,J. and Siigur,E.
    Activation of factor X by snake venom proteases
    447-464. DOI
  134. Straub,A., Roehrig,S. and Hillisch,A.
    Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?
    Angew Chem Int Ed Engl50, 4574-4590. PubMed  Europe PubMed DOI  I
    135. 2010
  135. Barone,A., Campbell,J., Griffin,G. and Hill,M.
    Factor X Umuahia: a severe bleeding diathesis associated with a novel mutation
    Pediatr Blood Cancer55, 1246-1246. PubMed  Europe PubMed DOI  M
  136. Borensztajn,K., Peppelenbosch,M.P. and Spek,C.A.
    Coagulation factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation
    Thromb Res125, e323-e328. PubMed  Europe PubMed DOI
  137. Gueguen,P., Cherel,G., Badirou,I., Denis,C.V. and Christophe,O.D.
    Two residues in the activation peptide domain contribute to the half-life of factor X in vivo
    J Thromb Haemost8, 1651-1653. PubMed  Europe PubMed DOI
  138. Huang,X., Dementiev,A., Olson,S.T. and Gettins,P.G.
    Basis for the specificity and activation of the serpin protein Z-dependent proteinase inhibitor (ZPI) as an inhibitor of membrane-associated factor Xa
    J Biol Chem285, 20399-20409. PubMed  Europe PubMed DOI
  139. Lee,C.J., Chandrasekaran,V., Wu,S., Duke,R.E. and Pedersen,L.G.
    Recent estimates of the structure of the factor VIIa (FVIIa)/tissue factor (TF) and factor Xa (FXa) ternary complex
    Thromb Res125 Suppl 1, S7-S7. PubMed  Europe PubMed DOI  S
  140. Talbot,K., Meixner,S.C. and Pryzdial,E.L.
    Enhanced fibrinolysis by proteolysed coagulation factor Xa
    Biochim Biophys Acta1804, 723-730. PubMed  Europe PubMed DOI
  141. Wallnoefer,H.G., Handschuh,S., Liedl,K.R. and Fox,T.
    Stabilizing of a globular protein by a highly complex water network: a molecular dynamics simulation study on factor Xa
    J Phys Chem B114, 7405-7412. PubMed  Europe PubMed DOI  S
    142. 2009
  142. Borensztajn,K., Bijlsma,M.F., Reitsma,P.H., Peppelenbosch,M.P. and Spek,C.A.
    Coagulation factor Xa inhibits cancer cell migration via protease-activated receptor-1 activation
    Thromb Res124, 219-225. PubMed  Europe PubMed DOI  U
  143. Chafa,O., Tagzirt,M., Tapon-Bretaudiere,J., Reghis,A., Fischer,A.M. and LeBonniec,B.F.
    Characterization of a homozygous Gly11Val mutation in the Gla domain of coagulation factor X
    Thromb Res124, 144-148. PubMed  Europe PubMed DOI  M
  144. Chen,Y., Qin,S., Tan,W., Lu,Y., Zhang,J., Li,H., Bu,H. and Cheng,J.
    Cloning and comparison of factor X from rhesus monkey (Macaca mulatta)
    Comp Med59, 476-481. PubMed  Europe PubMed
  145. Glauser,B.F., Rezende,R.M., Melo,F.R., Pereira,M.S., Francischetti,I.M., Monteiro,R.Q., Rezaie,A.R. and Mourao,P.A.
    Anticoagulant activity of a sulfated galactan: serpin-independent effect and specific interaction with factor Xa
    Thromb Haemost102, 1183-1193. PubMed  Europe PubMed DOI
  146. Menegatti,M. and Peyvandi,F.
    Factor X deficiency
    Semin Thromb Hemost35, 407-415. PubMed  Europe PubMed DOI  M
  147. Monti,M., Borensztajn,K.S., Pinotti,M., Canella,A., Branchini,A., Marchetti,G., Reitsma,P.H., Bernardi,F. and Spek,C.A.
    Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity
    Thromb Res123, 914-918. PubMed  Europe PubMed DOI
  148. Rosborough,T.K., Jacobsen,J.M. and Shepherd,M.F.
    Relationship between chromogenic factor X and international normalized ratio differs during early warfarin initiation compared with chronic warfarin administration
    Blood Coagul Fibrinolysis20, 433-435. PubMed  Europe PubMed DOI  A
  149. Salonen,L.M., Bucher,C., Banner,D.W., Haap,W., Mary,J.L., Benz,J., Kuster,O., Seiler,P., Schweizer,W.B. and Diederich,F.
    Cation-pi interactions at the active site of factor Xa: dramatic enhancement upon stepwise N-alkylation of ammonium ions
    Angew Chem Int Ed Engl48, 811-814. PubMed  Europe PubMed DOI
  150. Van Huis,C.A., Casimiro-Garcia,A., Bigge,C.F., Cody,W.L., Dudley,D.A., Filipski,K.J., Heemstra,R.J., Kohrt,J.T., Leadley,R.J., Jr., Narasimhan,L.S., McClanahan,T., Mochalkin,I., Pamment,M., Peterson,J.T., Sahasrabudhe,V., Schaum,R.P. and Edmunds,J.J.
    Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active factor Xa inhibitors with extended duration of action
    Bioorg Med Chem17, 2501-2511. PubMed  Europe PubMed DOI  I
  151. Verghese,J., Liang,A., Sidhu,P.P., Hindle,M., Zhou,Q. and Desai,U.R.
    First steps in the direction of synthetic, allosteric, direct inhibitors of thrombin and factor Xa
    Bioorg Med Chem Lett19, 4126-4129. PubMed  Europe PubMed DOI  I
  152. Wong,P.C., Crain,E.J., Watson,C.A. and Xin,B.
    Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits
    J Thromb Haemost7, 1313-1320. PubMed  Europe PubMed DOI  I
  153. Zikria,J.C. and Ansell,J.
    Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change
    Curr Opin Hematol16, 347-356. PubMed  Europe PubMed DOI  I
    154. 2008
  154. Abboud,M.A., Needle,S.J., Burns-Kurtis,C.L., Valocik,R.E., Koster,P.F., Amour,A.J., Chan,C., Brown,D., Chaudry,L., Zhou,P., Patikis,A., Patel,C., Pateman,A.J., Young,R.J., Watson,N.S. and Toomey,J.R.
    Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor
    J Cardiovasc Pharmacol52, 66-71. PubMed  Europe PubMed DOI  I
  155. Bereczky,Z., Bardos,H., Komaromi,I., Kiss,C., Haramura,G., Ajzner,E., Adany,R. and Muszbek,L.
    Factor X Debrecen: Gly204Arg mutation in factor X causes the synthesis of a non-secretable protein and severe factor X deficiency
    Haematologica93, 299-302. PubMed  Europe PubMed DOI  M
  156. Brown,D.L. and Kouides,P.A.
    Diagnosis and treatment of inherited factor X deficiency
    Haemophilia14, 1176-1182. PubMed  Europe PubMed DOI  M  V
  157. Chen,C.T., Yang,E.W., Hsu,H.J., Sun,Y.K., Hsu,W.L. and Yang,A.S.
    Protease substrate site predictors derived from machine learning on multilevel substrate phage display data
    Bioinformatics24, 2691-2697. PubMed  Europe PubMed DOI  P
  158. Corte,J.R., Fang,T., Pinto,D.J., Han,W., Hu,Z., Jiang,X.J., Li,Y.L., Gauuan,J.F., Hadden,M., Orton,D., Rendina,A.R., Luettgen,J.M., Wong,P.C., He,K., Morin,P.E., Chang,C.H., Cheney,D.L., Knabb,R.M., Wexler,R.R. and Lam,P.Y.
    Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties
    Bioorg Med Chem Lett18, 2845-2849. PubMed  Europe PubMed DOI  I
  159. Furugohri,T., Isobe,K., Honda,Y., Kamisato-Matsumoto,C., Sugiyama,N., Nagahara,T., Morishima,Y. and Shibano,T.
    DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles
    J Thromb Haemost6, 1542-1549. PubMed  Europe PubMed DOI  I
  160. Hsu,H.J., Tsai,K.C., Sun,Y.K., Chang,H.J., Huang,Y.J., Yu,H.M., Lin,C.H., Mao,S.S. and Yang,A.S.
    Factor Xa active site substrate specificity with substrate phage display and computational molecular modeling
    J Biol Chem283, 12343-12353. PubMed  Europe PubMed DOI  P
  161. Imaeda,Y., Miyawaki,T., Sakamoto,H., Itoh,F., Konishi,N., Hiroe,K., Kawamura,M., Tanaka,T. and Kubo,K.
    Discovery of sulfonylalkylamides: a new class of orally active factor Xa inhibitors
    Bioorg Med Chem16, 2243-2260. PubMed  Europe PubMed DOI  I
  162. Lee,Y.K., Parks,D.J., Lu,T., Thieu,T.V., Markotan,T., Pan,W., McComsey,D.F., Milkiewicz,K.L., Crysler,C.S., Ninan,N., Abad,M.C., Giardino,E.C., Maryanoff,B.E., Damiano,B.P. and Player,M.R.
    7-fluoroindazoles as potent and selective inhibitors of factor Xa
    J Med Chem51, 282-297. PubMed  Europe PubMed DOI  S  I
  163. Qiao,J.X., Cheney,D.L., Alexander,R.S., Smallwood,A.M., King,S.R., He,K., Rendina,A.R., Luettgen,J.M., Knabb,R.M., Wexler,R.R. and Lam,P.Y.
    Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa
    Bioorg Med Chem Lett18, 4118-4123. PubMed  Europe PubMed DOI  S  I
  164. Shi,Y., Sitkoff,D., Zhang,J., Klei,H.E., Kish,K., Liu,E.C., Hartl,K.S., Seiler,S.M., Chang,M., Huang,C., Youssef,S., Steinbacher,T.E., Schumacher,W.A., Grazier,N., Pudzianowski,A., Apedo,A., Discenza,L., Yanchunas,J., Stein,P.D. and Atwal,K.S.
    Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors
    J Med Chem51, 7541-7551. PubMed  Europe PubMed DOI  S  I
  165. Smallheer,J.M., Wang,S., Laws,M.L., Nakajima,S., Hu,Z., Han,W., Jacobson,I., Luettgen,J.M., Rossi,K.A., Rendina,A.R., Knabb,R.M., Wexler,R.R., Lam,P.Y. and Quan,M.L.
    Sulfonamidolactam inhibitors of coagulation factor Xa
    Bioorg Med Chem Lett18, 2428-2433. PubMed  Europe PubMed DOI  I
  166. Tai,S.J., Herzog,R.W., Margaritis,P., Arruda,V.R., Chu,K., Golden,J.A., Labosky,P.A. and High,K.A.
    A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X
    J Thromb Haemost6, 339-345. PubMed  Europe PubMed DOI  K
  167. Toso,R., Zhu,H. and Camire,R.M.
    The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly
    J Biol Chem283, 18627-18635. PubMed  Europe PubMed DOI
  168. Young,R.J., Borthwick,A.D., Brown,D., Burns-Kurtis,C.L., Campbell,M., Chan,C., Charbaut,M., Chung,C.W., Convery,M.A., Kelly,H.A., Paul King,N., Kleanthous,S., Mason,A.M., Pateman,A.J., Patikis,A.N., Pinto,I.L., Pollard,D.R., Senger,S., Shah,G.P., Toomey,J.R., Watson,N.S. and Weston,H.E.
    Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs
    Bioorg Med Chem Lett18, 23-27. PubMed  Europe PubMed DOI  I
  169. Young,R.J., Borthwick,A.D., Brown,D., Burns-Kurtis,C.L., Campbell,M., Chan,C., Charbaut,M., Convery,M.A., Diallo,H., Hortense,E., Irving,W.R., Kelly,H.A., King,N.P., Kleanthous,S., Mason,A.M., Pateman,A.J., Patikis,A.N., Pinto,I.L., Pollard,D.R., Senger,S., Shah,G.P., Toomey,J.R., Watson,N.S., Weston,H.E. and Zhou,P.
    Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs
    Bioorg Med Chem Lett18, 28-33. PubMed  Europe PubMed DOI  I
    170. 2007
  170. Ansell,J.
    Factor Xa or thrombin: is factor Xa a better target?
    J Thromb Haemost5 Suppl 1, 60-64. PubMed  Europe PubMed DOI  V
  171. Borensztajn,K.S., Bijlsma,M.F., Groot,A.P., Bruggemann,L.W., Versteeg,H.H., Reitsma,P.H., Peppelenbosch,M.P. and Spek,C.A.
    Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation
    Exp Cell Res313, 2622-2633. PubMed  Europe PubMed DOI
  172. Chan,C., Borthwick,A.D., Brown,D., Burns-Kurtis,C.L., Campbell,M., Chaudry,L., Chung,C.W., Convery,M.A., Hamblin,J.N., Johnstone,L., Kelly,H.A., Kleanthous,S., Patikis,A., Patel,C., Pateman,A.J., Senger,S., Shah,G.P., Toomey,J.R., Watson,N.S., Weston,H.E., Whitworth,C., Young,R.J. and Zhou,P.
    Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides
    J Med Chem50, 1546-1557. PubMed  Europe PubMed DOI  S  I
  173. Di Fenza,A., Heine,A., Koert,U. and Klebe,G.
    Understanding binding selectivity toward trypsin and factor Xa: the role of aromatic interactions
    ChemMedChem2, 297-308. PubMed  Europe PubMed DOI  I
  174. Donnecke,D., Schweinitz,A., Sturzebecher,A., Steinmetzer,P., Schuster,M., Sturzebecher,U., Nicklisch,S., Sturzebecher,J. and Steinmetzer,T.
    From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3
    Bioorg Med Chem Lett17, 3322-3329. PubMed  Europe PubMed DOI  I
  175. Du,L., Kao,R.Y., Zhou,Y., He,Y., Zhao,G., Wong,C., Jiang,S., Yuen,K.Y., Jin,D.Y. and Zheng,B.J.
    Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity
    Biochem Biophys Res Commun359, 174-179. PubMed  Europe PubMed DOI  I
  176. Franciskovich,J.B., Masters,J.J., Weber,W.W., Klimkowski,V.J., Chouinard,M., Sipes,P.R., Johnson,L.M., Snyder,D.W., Chastain,M.K., Craft,T.J., Towner,R.D., Gifford-Moore,D.S., Froelich,L.L., Smallwood,J.K., Foster,R.S., Smith,G.F., Liebeschuetz,J.W., Murray,C.W. and Young,S.C.
    Investigation of the terminal P4 domain in a series of d-phenylglycinamide-based factor Xa inhibitors
    Bioorg Med Chem Lett17, 6910-6913. PubMed  Europe PubMed DOI  I
  177. Gale,A.J., Yegneswaran,S., Xu,X., Pellequer,J.L. and Griffin,J.H.
    Characterization of a factor Xa binding site on factor Va near the Arg-506 activated protein C cleavage site
    J Biol Chem282, 21848-21855. PubMed  Europe PubMed DOI
  178. Graff,J., von Hentig,N., Misselwitz,F., Kubitza,D., Becka,M., Breddin,H.K. and Harder,S.
    Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity
    J Clin Pharmacol47, 1398-1407. PubMed  Europe PubMed DOI  I
  179. Guertin,K.R. and Choi,Y.M.
    The discovery of the factor Xa inhibitor otamixaban: from lead identification to clinical development
    Curr Med Chem14, 2471-2481. PubMed  Europe PubMed DOI  I
  180. Kohrt,J.T., Bigge,C.F., Bryant,J.W., Casimiro-Garcia,A., Chi,L., Cody,W.L., Dahring,T., Dudley,D.A., Filipski,K.J., Haarer,S., Heemstra,R., Janiczek,N., Narasimhan,L., McClanahan,T., Peterson,J.T., Sahasrabudhe,V., Schaum,R., Van Huis,C.A., Welch,K.M., Zhang,E., Leadley,R.J. and Edmunds,J.J.
    The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor
    Chem Biol Drug Des70, 100-112. PubMed  Europe PubMed DOI  I
  181. Levigne,S., Thiec,F., Cherel,G., Irving,J.A., Fribourg,C. and Christophe,O.D.
    Role of the alpha-helix 163-170 in factor Xa catalytic activity
    J Biol Chem282, 31569-31579. PubMed  Europe PubMed DOI
  182. Murakami,M.T., Rios-Steiner,J., Weaver,S.E., Tulinsky,A., Geiger,J.H. and Arni,R.K.
    Intermolecular interactions and characterization of the novel factor Xa exosite involved in macromolecular recognition and inhibition: crystal structure of human Gla-domainless factor Xa complexed with the anticoagulant protein NAPc2 from the hematophagous nematode Ancylostoma caninum
    J Mol Biol366, 602-610. PubMed  Europe PubMed DOI  S
  183. Nagata,T., Yoshino,T., Haginoya,N., Yoshikawa,K., Isobe,Y., Furugohri,T. and Kanno,H.
    Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors
    Bioorg Med Chem Lett17, 4683-4688. PubMed  Europe PubMed DOI  I
  184. Pinto,D.J., Orwat,M.J., Koch,S., Rossi,K.A., Alexander,R.S., Smallwood,A., Wong,P.C., Rendina,A.R., Luettgen,J.M., Knabb,R.M., He,K., Xin,B., Wexler,R.R. and Lam,P.Y.
    Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
    J Med Chem50, 5339-5356. PubMed  Europe PubMed DOI  I
  185. Qiao,J.X., Chang,C.H., Cheney,D.L., Morin,P.E., Wang,G.Z., King,S.R., Wang,T.C., Rendina,A.R., Luettgen,J.M., Knabb,R.M., Wexler,R.R. and Lam,P.Y.
    SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation factor Xa
    Bioorg Med Chem Lett17, 4419-4427. PubMed  Europe PubMed DOI  S  I
  186. Rios-Steiner,J.L., Murakami,M.T., Tulinsky,A. and Arni,R.K.
    Active and exo-site inhibition of human factor Xa: structure of des-Gla factor Xa inhibited by NAP5, a potent nematode anticoagulant protein from Ancylostoma caninum
    J Mol Biol371, 774-786. PubMed  Europe PubMed DOI  S
  187. Shinagawa,K., Martin,J.A., Ploplis,V.A. and Castellino,F.J.
    Coagulation factor Xa modulates airway remodeling in a murine model of asthma
    Am J Respir Crit Care Med175, 136-143. PubMed  Europe PubMed DOI
  188. Van Huis,C.A., Bigge,C.F., Casimiro-Garcia,A., Cody,W.L., Dudley,D.A., Filipski,K.J., Heemstra,R.J., Kohrt,J.T., Narasimhan,L.S., Schaum,R.P., Zhang,E., Bryant,J.W., Haarer,S., Janiczek,N., Leadley,R.J., Jr., McClanahan,T., Thomas Peterson,J., Welch,K.M. and Edmunds,J.J.
    Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors
    Chem Biol Drug Des69, 444-450. PubMed  Europe PubMed DOI  S  I
  189. Weitz,J.I.
    Factor Xa or thrombin: is thrombin a better target?
    J Thromb Haemost5 Suppl 1, 65-67. PubMed  Europe PubMed DOI  V  T
  190. Ye,B., Arnaiz,D.O., Chou,Y.L., Griedel,B.D., Karanjawala,R., Lee,W., Morrissey,M.M., Sacchi,K.L., Sakata,S.T., Shaw,K.J., Wu,S.C., Zhao,Z., Adler,M., Cheeseman,S., Dole,W.P., Ewing,J., Fitch,R., Lentz,D., Liang,A., Light,D., Morser,J., Post,J., Rumennik,G., Subramanyam,B., Sullivan,M.E., Vergona,R., Walters,J., Wang,Y.X., White,K.A., Whitlow,M. and Kochanny,M.J.
    Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors
    J Med Chem50, 2967-2980. PubMed  Europe PubMed DOI  I
  191. Young,R.J., Brown,D., Burns-Kurtis,C.L., Chan,C., Convery,M.A., Hubbard,J.A., Kelly,H.A., Pateman,A.J., Patikis,A., Senger,S., Shah,G.P., Toomey,J.R., Watson,N.S. and Zhou,P.
    Selective and dual action orally active inhibitors of thrombin and factor Xa
    Bioorg Med Chem Lett17, 2927-2930. PubMed  Europe PubMed DOI  I
    192. 2006
  192. [YEAR:28-3-2006]Auerswald,G.
    Prophylaxis in rare coagulation disorders-factor X deficiency
    Thromb Res118 Suppl 1, S29-S31. PubMed  Europe PubMed DOI
  193. Becker,R.C., Alexander,J.H., Dyke,C., Huang,Y., Saint-Jacques,H., Hasselblad,V., Harrington,R.A. and Bovill,E.G.
    Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease
    Thromb Res117, 439-446. PubMed  Europe PubMed DOI  I
  194. [YEAR:6-5-2006]Fevig,J.M., Cacciola,J., Buriak,J., Jr., Rossi,K.A., Knabb,R.M., Luettgen,J.M., Wong,P.C., Bai,S.A., Wexler,R.R. and Lam,P.Y.
    Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa
    Bioorg Med Chem Lett16, 3755-3760. PubMed  Europe PubMed DOI  I
  195. Graefe-Mody,E.U., Schuhly,U., Rathgen,K., Stahle,H., Leitner,J.M. and Jilma,B.
    Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa
    J Thromb Haemost4, 1502-1509. PubMed  Europe PubMed DOI  I
  196. [YEAR:3-5-2006]Johnson,D.J., Li,W., Adams,T.E. and Huntington,J.A.
    Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation
    EMBO J25, 2029-2037. PubMed  Europe PubMed DOI  S
  197. Kohrt,J.T., Filipski,K.J., Cody,W.L., Bigge,C.F., La,F., Welch,K., Dahring,T., Bryant,J.W., Leonard,D., Bolton,G., Narasimhan,L., Zhang,E., Peterson,J.T., Haarer,S., Sahasrabudhe,V., Janiczek,N., Desiraju,S., Hena,M., Fiakpui,C., Saraswat,N., Sharma,R., Sun,S., Maiti,S.N., Leadley,R. and Edmunds,J.J.
    The discovery of glycine and related amino acid-based factor Xa inhibitors
    Bioorg Med Chem14, 4379-4392. PubMed  Europe PubMed DOI  S  I
  198. [YEAR:24-7-2006]Li,Y.L., Fevig,J.M., Cacciola,J., Buriak,J., Jr., Rossi,K.A., Jona,J., Knabb,R.M., Luettgen,J.M., Wong,P.C., Bai,S.A., Wexler,R.R. and Lam,P.Y.
    Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa
    Bioorg Med Chem Lett16, 5176-5182. PubMed  Europe PubMed DOI  I
  199. Matsushita,K., Imamura,T., Tancharoen,S., Tatsuyama,S., Tomikawa,M., Travis,J., Potempa,J., Torii,M. and Maruyama,I.
    Selective inhibition of Porphyromonas gingivalis growth by a factor Xa inhibitor, DX-9065a
    J Periodontal Res41, 171-176. PubMed  Europe PubMed DOI  I
  200. [YEAR:25-5-2006]Pinto,D.J., Orwat,M.J., Quan,M.L., Han,Q., Galemmo,R.A., Jr., Amparo,E., Wells,B., Ellis,C., He,M.Y., Alexander,R.S., Rossi,K.A., Smallwood,A., Wong,P.C., Luettgen,J.M., Rendina,A.R., Knabb,R.M., Mersinger,L., Kettner,C., Bai,S., He,K., Wexler,R.R. and Lam,P.Y.
    1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
    Bioorg Med Chem Lett16, 4141-4147. PubMed  Europe PubMed DOI  I
  201. [YEAR:8-9-2006]Pinto,D.J., Galemmo,R.A., Jr., Quan,M.L., Orwat,M.J., Clark,C., Li,R., Wells,B., Woerner,F., Alexander,R.S., Rossi,K.A., Smallwood,A., Wong,P.C., Luettgen,J.M., Rendina,A.R., Knabb,R.M., He,K., Wexler,R.R. and Lam,P.Y.
    Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties
    Bioorg Med Chem Lett16, 5584-5589. PubMed  Europe PubMed DOI  I
  202. Rezaie,A.R.
    Determinants of specificity of factor Xa interaction with its physiological inhibitors
    Mini Rev Med Chem6, 859-865. PubMed  Europe PubMed DOI
  203. [YEAR:25-4-2006]Rezaie,A.R.
    Pentasaccharide enhances the inactivation of factor Xa by antithrombin by promoting the assembly of a Michaelis-type intermediate complex. Demonstration by rapid kinetic, surface plasmon resonance, and competitive binding studies
    Biochemistry45, 5324-5329. PubMed  Europe PubMed DOI
  204. Schweinitz,A., Sturzebecher,A., Sturzebecher,U., Schuster,O., Sturzebecher,J. and Steinmetzer,T.
    New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue: part 1
    Med Chem2, 349-361. PubMed  Europe PubMed DOI  I
  205. Senger,S., Convery,M.A., Chan,C. and Watson,N.S.
    Arylsulfonamides: a study of the relationship between activity and conformational preferences for a series of factor Xa inhibitors
    Bioorg Med Chem Lett16, 5731-5735. PubMed  Europe PubMed DOI  I
  206. Siigur,J. and Siigur,E.
    Factor X activating proteases from snake venoms
    J Toxicol Toxin Rev25, 235-255.  V
  207. Watson,N.S., Brown,D., Campbell,M., Chan,C., Chaudry,L., Convery,M.A., Fenwick,R., Hamblin,J.N., Haslam,C., Kelly,H.A., King,N.P., Kurtis,C.L., Leach,A.R., Manchee,G.R., Mason,A.M., Mitchell,C., Patel,C., Patel,V.K., Senger,S., Shah,G.P., Weston,H.E., Whitworth,C. and Young,R.J.
    Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
    Bioorg Med Chem Lett16, 3784-3788. PubMed  Europe PubMed DOI  S  I
  208. Young,R.J., Campbell,M., Borthwick,A.D., Brown,D., Burns-Kurtis,C.L., Chan,C., Convery,M.A., Crowe,M.C., Dayal,S., Diallo,H., Kelly,H.A., King,N.P., Kleanthous,S., Mason,A.M., Mordaunt,J.E., Patel,C., Pateman,A.J., Senger,S., Shah,G.P., Smith,P.W., Watson,N.S., Weston,H.E. and Zhou,P.
    Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs
    Bioorg Med Chem Lett16, 5953-5957. PubMed  Europe PubMed DOI  I
    209. 2005
  209. Banke,I.J., Arlt,M.J., Mueller,M.M., Sperl,S., Stemberger,A., Sturzebecher,J., Amirkhosravi,A., Moroder,L. and Kruger,A.
    Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity
    Thromb Haemost94, 1084-1093. PubMed  Europe PubMed DOI  I
  210. [YEAR:19-7-2005]Bianchini,E.P., Orcutt,S.J., Panizzi,P., Bock,P.E. and Krishnaswamy,S.
    Ratcheting of the substrate from the zymogen to proteinase conformations directs the sequential cleavage of prothrombin by prothrombinase
    Proc Natl Acad Sci U S A102, 10099-10104. PubMed  Europe PubMed DOI
  211. [YEAR:1-9-2005]Franciskovich,J.B., Masters,J.J., Tinsley,J.M., Craft,T.J., Froelich,L.L., Gifford-Moore,D.S., Klimkowski,V.J., Smallwood,J.K., Smith,G.F., Smith,T., Towner,R.R., Weir,L.C. and Wiley,M.R.
    Investigation of factor Xa inhibitors containing non-amidine S1 elements
    Bioorg Med Chem Lett15, 4838-4841. PubMed  Europe PubMed DOI  I
  212. Komoriya,S., Haginoya,N., Kobayashi,S., Nagata,T., Mochizuki,A., Suzuki,M., Yoshino,T., Horino,H., Nagahara,T., Suzuki,M., Isobe,Y. and Furugoori,T.
    Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites
    Bioorg Med Chem13, 3927-3954. PubMed  Europe PubMed DOI  S  I
  213. [YEAR:15-2-2005]Koshio,H., Hirayama,F., Ishihara,T., Shiraki,R., Shigenaga,T., Taniuchi,Y., Sato,K., Moritani,Y., Iwatsuki,Y., Kaku,S., Katayama,N., Kawasaki,T., Matsumoto,Y., Sakamoto,S. and Tsukamoto,S.
    Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors
    Bioorg Med Chem13, 1305-1323. PubMed  Europe PubMed DOI  I
  214. Kumar,A., Mishra,K.L., Kumar,A. and Mishra,D.
    Hereditary coagulation factor X deficiency
    Indian Pediatr42, 1240-1242. PubMed  Europe PubMed  M
  215. [YEAR:2-8-2005]Manithody,C. and Rezaie,A.R.
    Functional mapping of charged residues of the 82-116 sequence in factor Xa: evidence that lysine 96 is a factor Va independent recognition site for prothrombin in the prothrombinase complex
    Biochemistry44, 10063-10070. PubMed  Europe PubMed DOI
  216. [YEAR:5-5-2005]Matter,H., Will,D.W., Nazare,M., Schreuder,H., Laux,V. and Wehner,V.
    Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions
    J Med Chem48, 3290-3312. PubMed  Europe PubMed DOI  I
  217. Nazare,M., Will,D.W., Matter,H., Schreuder,H., Ritter,K., Urmann,M., Essrich,M., Bauer,A., Wagner,M., Czech,J., Lorenz,M., Laux,V. and Wehner,V.
    Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography
    J Med Chem48, 4511-4525. PubMed  Europe PubMed DOI  S  I
  218. Quan,M.L., Lam,P.Y., Han,Q., Pinto,D.J., He,M.Y., Li,R., Ellis,C.D., Clark,C.G., Teleha,C.A., Sun,J.H., Alexander,R.S., Bai,S., Luettgen,J.M., Knabb,R.M., Wong,P.C. and Wexler,R.R.
    Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor
    J Med Chem48, 1729-1744. PubMed  Europe PubMed DOI  I
  219. Reza,A., Swarup,S. and Manjunatha Kini,R.
    Two parallel prothrombin activator systems in Australian rough-scaled snake, Tropidechis carinatus. Structural comparison of venom prothrombin activator with blood coagulation factor X
    Thromb Haemost93, 40-47. PubMed  Europe PubMed DOI
  220. Reza,M.A., Swarup,S. and Kini,R.M.
    Gene structures of trocarin D and coagulation factor X, two functionally diverse prothrombin activators from Australian rough scaled snake
    Pathophysiol Haemost Thromb34, 205-208. PubMed  Europe PubMed DOI
  221. [YEAR:3-8-2005]Rezaie,A.R., Manithody,C. and Yang,L.
    Identification of factor Xa residues critical for interaction with protein Z-dependent protease inhibitor: both active site and exosite interactions are required for inhibition
    J Biol Chem280, 32722-32728. PubMed  Europe PubMed DOI
  222. Scharer,K., Morgenthaler,M., Paulini,R., Obst-Sander,U., Banner,D.W., Schlatter,D., Benz,J., Stihle,M. and Diederich,F.
    Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of factor Xa bound to a quaternary ammonium ion ligand
    Angew Chem Int Ed Engl44, 4400-4404. PubMed  Europe PubMed DOI  S
  223. Volkel,T., Heidtmann,H.H., Muller,R. and Kontermann,R.E.
    Engineering of human coagulation factor X variants activated by prostate-specific antigen
    Mol Biotechnol29, 19-30. PubMed  Europe PubMed DOI
    224. 2004
  224. [YEAR:1-11-2004]Batt,D.G., Qiao,J.X., Modi,D.P., Houghton,G.C., Pierson,D.A., Rossi,K.A., Luettgen,J.M., Knabb,R.M., Jadhav,P.K. and Wexler,R.R.
    5-Amidinoindoles as dual inhibitors of coagulation factors IXa and Xa
    Bioorg Med Chem Lett14, 5269-5273. PubMed  Europe PubMed DOI  I
  225. Becker,R.C., Alexander,J., Dyke,C.K. and Harrington,R.A.
    Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease
    Thromb Haemost92, 1182-1193. PubMed  Europe PubMed DOI  I
  226. Brown,M.A., Stenberg,L.M. and Stenflo,J.
    Coagulation factor X
    [ISSN:0-12-079610-4]2, 1662-1666.  V
  227. Girolami,A., Vianello,F., Cabrio,L. and Lombardi,A.M.
    A new mutation (Arg251Trp) in the Ca2+ binding site of factor X protease domain appears to be responsible for the defect in the extrinsic pathway activation of factor X Padua
    Clin Appl Thromb Hemost10, 5-8. PubMed  Europe PubMed
  228. Haginoya,N., Kobayashi,S., Komoriya,S., Yoshino,T., Suzuki,M., Shimada,T., Watanabe,K., Hirokawa,Y., Furugori,T. and Nagahara,T.
    Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element
    J Med Chem47, 5167-5182. PubMed  Europe PubMed DOI  S  I
  229. Ieko,M., Tarumi,T., Takeda,M., Naito,S., Nakabayashi,T. and Koike,T.
    Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis
    J Thromb Haemost2, 612-618. PubMed  Europe PubMed DOI  I
  230. [YEAR:1-5-2004]Komoriya,S., Kanaya,N., Nagahara,T., Yokoyama,A., Inamura,K., Yokoyama,Y., Katakura,S. and Hara,T.
    Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites
    Bioorg Med Chem12, 2099-2114. PubMed  Europe PubMed DOI  V  I
  231. [YEAR:15-10-2004]Koshio,H., Hirayama,F., Ishihara,T., Kaizawa,H., Shigenaga,T., Taniuchi,Y., Sato,K., Moritani,Y., Iwatsuki,Y., Uemura,T., Kaku,S., Kawasaki,T., Matsumoto,Y., Sakamoto,S. and Tsukamoto,S.
    Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives
    Bioorg Med Chem12, 5415-5426. PubMed  Europe PubMed DOI  I
  232. [YEAR:1-5-2004]Koshio,H., Hirayama,F., Ishihara,T., Taniuchi,Y., Sato,K., Sakai-Moritani,Y., Kaku,S., Kawasaki,T., Matsumoto,Y., Sakamoto,S. and Tsukamoto,S.
    Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity
    Bioorg Med Chem12, 2179-2191. PubMed  Europe PubMed DOI  I
  233. Kranjc,A. and Kikelj,D.
    Dual inhibitors of the blood coagulation enzymes
    Curr Med Chem11, 2535-2547. PubMed  Europe PubMed
  234. [YEAR:6-12-2004]Mederski,W.W., Cezanne,B., van Amsterdam,C., Buhring,K.U., Dorsch,D., Gleitz,J., Marz,J. and Tsaklakidis,C.
    Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa
    Bioorg Med Chem Lett14, 5817-5822. PubMed  Europe PubMed DOI  I
  235. [YEAR:7-6-2004]Nazare,M., Matter,H., Klingler,O., Al-Obeidi,F., Schreuder,H., Zoller,G., Czech,J., Lorenz,M., Dudda,A., Peyman,A., Nestler,H.P., Urmann,M., Bauer,A., Laux,V., Wehner,V. and Will,D.W.
    Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand
    Bioorg Med Chem Lett14, 2801-2805. PubMed  Europe PubMed DOI  I
  236. [YEAR:24-12-2004]Orcutt,S.J. and Krishnaswamy,S.
    Binding of substrate in two conformations to human prothrombinase drives consecutive cleavage at two sites in prothrombin
    J Biol Chem279, 54927-54936. PubMed  Europe PubMed DOI
  237. [YEAR:30-3-2004]Rezaie,A.R.
    Kinetics of factor Xa inhibition by recombinant tick anticoagulant peptide: both active site and exosite interactions are required for a slow- and tight-binding inhibition mechanism
    Biochemistry43, 3368-3375. PubMed  Europe PubMed DOI
  238. [YEAR:16-3-2004]Rezaie,A.R., Yang,L. and Manithody,C.
    Mutagenesis studies toward understanding the mechanism of differential reactivity of factor Xa with the native and heparin-activated antithrombin
    Biochemistry43, 2898-2905. PubMed  Europe PubMed DOI
  239. [YEAR:18-10-2004]Rumthao,S., Lee,O., Sheng,Q., Fu,W., Mulhearn,D.C., Crich,D., Mesecar,A.D. and Johnson,M.E.
    Design, synthesis, and evaluation of oxyanion-hole selective inhibitor substituents for the S1 subsite of factor Xa
    Bioorg Med Chem Lett14, 5165-5170. PubMed  Europe PubMed DOI  I
  240. [YEAR:29-7-2004]Willardsen,J.A., Dudley,D.A., Cody,W.L., Chi,L., McClanahan,T.B., Mertz,T.E., Potoczak,R.E., Narasimhan,L.S., Holland,D.R., Rapundalo,S.T. and Edmunds,J.J.
    Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa
    J Med Chem47, 4089-4099. PubMed  Europe PubMed DOI  I
    241. 2003
  241. [YEAR:28-2-2003]Brufatto,N. and Nesheim,M.E.
    Analysis of the kinetics of prothrombin activation and evidence that two equilibrating forms of prothrombinase are involved in the process
    J Biol Chem278, 6755-6764. PubMed  Europe PubMed DOI
  242. [YEAR:27-2-2003]Choi-Sledeski,Y.M., Kearney,R., Poli,G., Pauls,H., Gardner,C., Gong,Y., Becker,M., Davis,R., Spada,A., Liang,G., Chu,V., Brown,K., Collussi,D., Leadley,R., Jr., Rebello,S., Moxey,P., Morgan,S., Bentley,R., Kasiewski,C., Maignan,S., Guilloteau,J.P. and Mikol,V.
    Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand
    J Med Chem46, 681-684. PubMed  Europe PubMed DOI  I
  243. Jenny,R.J., Mann,K.G. and Lundblad,R.L.
    A critical review of the methods for cleavage of fusion proteins with thrombin and factor Xa
    Protein Expr Purif31, 1-11. PubMed  Europe PubMed DOI
  244. [YEAR:25-6-2003]Josic,D., Hoffer,L. and Buchacher,A.
    Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C
    J Chromatogr B Analyt Technol Biomed Life Sci790, 183-197. PubMed  Europe PubMed DOI
  245. Ludeman,J.P., Pike,R.N., Bromfield,K.M., Duggan,P.J., Cianci,J., Le Bonniec,B., Whisstock,J.C. and Bottomley,S.P.
    Determination of the P1', P2' and P3' subsite-specificity of factor Xa
    Int J Biochem Cell Biol35, 221-225. PubMed  Europe PubMed DOI
  246. Maignan,S., Guilloteau,J.P., Choi-Sledeski,Y.M., Becker,M.R., Ewing,W.R., Pauls,H.W., Spada,A.P. and Mikol,V.
    Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket
    J Med Chem46, 685-690. PubMed  Europe PubMed DOI  S  I
  247. Nogami,K., Wakabayashi,H. and Fay,P.J.
    Mechanisms of factor Xa-catalyzed cleavage of the factor VIIIa A1 subunit resulting in cofactor inactivation
    J Biol Chem278, 16502-16509. PubMed  Europe PubMed DOI
  248. Oliva,M.L., Andrade,S.A., Juliano,M.A., Sallai,R.C., Torquato,R.J., Sampaio,M.U., Pott,V.J. and Sampaio,C.A.
    Kinetic characterization of factor Xa binding using a quenched fluorescent substrate based on the reactive site of factor Xa inhibitor from Bauhinia ungulata seeds
    Curr Med Chem10, 1085-1093. PubMed  Europe PubMed DOI
  249. [YEAR:31-1-2003]Reyda,S., Sohn,C., Klebe,G., Rall,K., Ullmann,D., Jakubke,H.D. and Stubbs,M.T.
    Reconstructing the binding site of factor Xa in trypsin reveals ligand-induced structural plasticity
    J Mol Biol325, 963-977. PubMed  Europe PubMed DOI
  250. [YEAR:21-7-2003]Ries,U.J., Priepke,H.W., Hauel,N.H., Handschuh,S., Mihm,G., Stassen,J.M., Wienen,W. and Nar,H.
    Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents
    Bioorg Med Chem Lett13, 2297-2302. PubMed  Europe PubMed DOI  I
  251. Sinha,U., Lin,P.H., Edwards,S.T., Wong,P.W., Zhu,B., Scarborough,R.M., Su,T., Jia,Z.J., Song,Y., Zhang,P., Clizbe,L., Park,G., Reed,A., Hollenbach,S.J., Malinowski,J. and Arfsten,A.E.
    Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitors
    Arterioscler Thromb Vasc Biol23, 1098-1104. PubMed  Europe PubMed DOI  I
  252. [YEAR:21-3-2003]Thiec,F., Cherel,G. and Christophe,O.D.
    Role of the Gla and first epidermal growth factor-like domains of factor X in the prothrombinase and tissue factor-factor VIIa complexes
    J Biol Chem278, 10393-10399. PubMed  Europe PubMed DOI
  253. Tomokiyo,K., Nakatomi,Y., Araki,T., Teshima,K., Nakano,H., Nakagaki,T., Miyamoto,S., Funatsu,A. and Iwanaga,S.
    A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone
    Vox Sang85, 290-299. PubMed  Europe PubMed DOI
  254. [YEAR:8-7-2003]Wang,S.X., Hur,E., Sousa,C.A., Brinen,L., Slivka,E.J. and Fletterick,R.J.
    The extended interactions and Gla domain of blood coagulation factor Xa
    Biochemistry42, 7959-7966. PubMed  Europe PubMed DOI  S
    255. 2002
  255. Adler,M., Kochanny,M.J., Ye,B., Rumennik,G., Light,D.R., Biancalana,S. and Whitlow,M.
    Crystal structures of two potent nonamidine inhibitors bound to factor Xa
    Biochemistry41, 15514-15523. PubMed  Europe PubMed DOI  S  I
  256. [YEAR:22-1-2002]Banerjee,M., Majumder,R., Weinreb,G., Wang,J. and Lentz,B.R.
    Role of procoagulant lipids in human prothrombin activation. 2. Soluble phosphatidylserine upregulates and directs factor X(a) to appropriate peptide bonds in prothrombin
    Biochemistry41, 950-957. PubMed  Europe PubMed DOI
  257. Bianchini,E.P., Louvain,V.B., Marque,P.E., Juliano,M.A., Juliano,L. and le Bonniec,B.F.
    Mapping of the catalytic groove preferences of factor Xa reveals an inadequate selectivity for its macromolecule substrates
    J Biol Chem277, 20527-20534. PubMed  Europe PubMed DOI  P
  258. [YEAR:4-10-2002]Camire,R.M.
    Prothrombinase assembly and S1 site occupation restore the catalytic activity of FXa impaired by mutation at the sodium-binding site
    J Biol Chem277, 37863-37870. PubMed  Europe PubMed DOI
  259. [YEAR:1-4-2002]Edwards,S.T., Betz,A., James,H.L., Thompson,E., Yonkovich,S.J. and Sinha,U.
    Differences between human and rabbit coagulation factor X - implications for in vivo models of thrombosis
    Thromb Res106, 71-79. PubMed  Europe PubMed DOI
  260. Guertin,K.R., Gardner,C.J., Klein,S.I., Zulli,A.L., Czekaj,M., Gong,Y., Spada,A.P., Cheney,D.L., Maignan,S., Guilloteau,J.P., Brown,K.D., Colussi,D.J., Chu,V., Heran,C.L., Morgan,S.R., Bentley,R.G., Dunwiddie,C.T., Leadley,R.J. and Pauls,H.W.
    Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity
    Bioorg Med Chem Lett12, 1671-1674. PubMed  Europe PubMed DOI  I
  261. [YEAR:22-2-2002]Harrison,L.M., Nerlinger,A., Bungiro,R.D., Cordova,J.L., Kuzmic,P. and Cappello,M.
    Molecular characterization of Ancylostoma inhibitors of coagulation factor Xa. Hookworm anticoagulant activity in vitro predicts parasite bloodfeeding in vivo
    J Biol Chem277, 6223-6229. PubMed  Europe PubMed DOI
  262. Liebeschuetz,J.W., Jones,S.D., Morgan,P.J., Murray,C.W., Rimmer,A.D., Roscoe,J.M., Waszkowycz,B., Welsh,P.M., Wylie,W.A., Young,S.C., Martin,H., Mahler,J., Brady,L. and Wilkinson,K.
    PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors
    J Med Chem45, 1221-1232. PubMed  Europe PubMed DOI  I
  263. Matsuda,Y., Shimokawa,K., Katayama,M., Shimizu,H., Umeda,T., Oshio,S. and Chiba,R.
    Blood coagulation factor X (FX) in human seminal plasma
    Arch Androl48, 295-300. PubMed  Europe PubMed DOI
  264. [YEAR:20-6-2002]Matter,H., Defossa,E., Heinelt,U., Blohm,P.M., Schneider,D., Muller,A., Herok,S., Schreuder,H., Liesum,A., Brachvogel,V., Lonze,P., Walser,A., Al-Obeidi,F. and Wildgoose,P.
    Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa
    J Med Chem45, 2749-2769. PubMed  Europe PubMed DOI  I
  265. Mueller,M.M., Sperl,S., Sturzebecher,J., Bode,W. and Moroder,L.
    (R)-3-Amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode
    Biol Chem383, 1185-1191. PubMed  Europe PubMed DOI  S  I
  266. Petitou,M., Duchaussoy,P., Herbert,J.M., Duc,G., El Hajji,M., Branellec,J.F., Donat,F., Necciari,J., Cariou,R., Bouthier,J. and Garrigou,E.
    The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa
    Semin Thromb Hemost28, 393-402. PubMed  Europe PubMed DOI  I
  267. [YEAR:6-5-2002]Shaw,K.J., Guilford,W.J., Griedel,B.D., Sakata,S., Trinh,L., Wu,S., Xu,W., Zhao,Z. and Morrissey,M.M.
    Benzimidazole-based fXa inhibitors with improved thrombin and trypsin selectivity
    Bioorg Med Chem Lett12, 1311-1314. PubMed  Europe PubMed DOI  I
  268. Steen,M.
    Factor Va-factor Xa interactions: molecular sites involved in enzyme:cofactor assembly
    Scand J Clin Lab Invest Suppl237, 5-11. PubMed  Europe PubMed
  269. Venkateswarlu,D., Perera,L., Darden,T. and Pedersen,L.G.
    Structure and dynamics of zymogen human blood coagulation factor X
    Biophys J82, 1190-1206. PubMed  Europe PubMed DOI
  270. [YEAR:22-1-2002]Wu,J.R., Zhou,C., Majumder,R., Powers,D.D., Weinreb,G. and Lentz,B.R.
    Role of procoagulant lipids in human prothrombin activation. 1. Prothrombin activation by factor X(a) in the absence of factor Va and in the absence and presence of membranes
    Biochemistry41, 935-949. PubMed  Europe PubMed DOI
  271. [YEAR:1-2-2002]Zhong,D., Bajaj,M.S., Schmidt,A.E. and Bajaj,S.P.
    The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor
    J Biol Chem277, 3622-3631. PubMed  Europe PubMed DOI
    272. 2001
  272. Monno,R., Grandaliano,G., Faccio,R., Ranieri,E., Martino,C., Gesualdo,L. and Schena,F.P.
    Activated coagulation factor X: A novel mitogenic stimulus for human mesangial cells
    J Am Soc Nephrol12, 891-899. PubMed  Europe PubMed
  273. [YEAR:15-2-2001]Pinto,D.J., Orwat,M.J., Wang,S., Fevig,J.M., Quan,M.L., Amparo,E., Cacciola,J., Rossi,K.A., Alexander,R.S., Smallwood,A.M., Luettgen,J.M., Liang,L., Aungst,B.J., Wright,M.R., Knabb,R.M., Wong,P.C., Wexler,R.R. and Lam,P.Y.
    Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4 -yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa
    J Med Chem44, 566-578. PubMed  Europe PubMed DOI  I
  274. Rai,R., Sprengeler,P.A., Elrod,K.C. and Young,W.B.
    Perspectives on factor Xa inhibition
    Curr Med Chem8, 101-119. PubMed  Europe PubMed
  275. [YEAR:15-4-2001]Rezaie,A.R.
    Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex
    Blood97, 2308-2313. PubMed  Europe PubMed DOI
  276. [YEAR:3-10-2001]Rezaie,A.R. and Yang,L.
    Probing the molecular basis of factor Xa specificity by mutagenesis of the serpin, antithrombin
    Biochim Biophys Acta1528, 167-176. PubMed  Europe PubMed DOI
  277. [YEAR:23-7-2001]Shrader,W.D., Young,W.B., Sprengeler,P.A., Sangalang,J.C., Elrod,K. and Carr,G.
    Neutral inhibitors of the serine protease factor Xa
    Bioorg Med Chem Lett11, 1801-1804. PubMed  Europe PubMed DOI  I
    278. 2000
  278. [YEAR:17-10-2000]Adler,M., Davey,D.D., Phillips,G.B., Kim,S.H., Jancarik,J., Rumennik,G., Light,D.R. and Whitlow,M.
    Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa
    Biochemistry39, 12534-12542. PubMed  Europe PubMed DOI  S  I
  279. [YEAR:21-11-2000]Camire,R.M., Larson,P.J., Stafford,D.W. and High,K.A.
    Enhanced gamma-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide
    Biochemistry39, 14322-14329. PubMed  Europe PubMed DOI
  280. Dewerchin,M., Liang,Z., Moons,L., Carmeliet,P., Castellino,F.J., Collen,D. and Rosen,E.D.
    Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice
    Thromb Haemost83, 185-190. PubMed  Europe PubMed  K
  281. [YEAR:5-7-2000]Harris,J.L., Backes,B.J., Leonetti,F., Mahrus,S., Ellman,J.A. and Craik,C.S.
    Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries
    Proc Natl Acad Sci U S A97, 7754-7759. PubMed  Europe PubMed DOI  P
  282. Katz,B.A., Mackman,R., Luong,C., Radika,K., Martelli,A., Sprengeler,P.A., Wang,J., Chan,H. and Wong,L.
    Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator
    Chem Biol7, 299-312. PubMed  Europe PubMed DOI  S
  283. Maignan,S., Guilloteau,J.P., Pouzieux,S., Choi-Sledeski,Y.M., Becker,M.R., Klein,S.I., Ewing,W.R., Pauls,H.W., Spada,A.P. and Mikol,V.
    Crystal structures of human factor Xa complexed with potent inhibitors
    J Med Chem43, 3226-3232. PubMed  Europe PubMed DOI  S  I
  284. Poorafshar,M., Aveskogh,M., Munday,B. and Hellman,L.
    Identification and structural analysis of four serine proteases in a monotreme, the platypus, Ornithorhynchus anatinus
    Immunogenetics52, 19-28. PubMed  Europe PubMed DOI
  285. [YEAR:22-2-2000]Rezaie,A.R. and He,X.
    Sodium binding site of factor Xa: Role of sodium in the prothrombinase complex
    Biochemistry39, 1817-1825. PubMed  Europe PubMed DOI
  286. Sperl,S., Bergner,A., Sturzebecher,J., Magdolen,V., Bode,W. and Moroder,L.
    Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies
    Biol Chem381, 321-329. PubMed  Europe PubMed DOI  S  I
  287. [YEAR:24-11-2000]Underwood,M.C., Zhong,D., Mathur,A., Heyduk,T. and Bajaj,S.P.
    Thermodynamic linkage between the S1 site, the Na+ site, and the Ca2+ site in the protease domain of human coagulation factor Xa. Studies on catalytic efficiency and inhibitor binding
    J Biol Chem275, 36876-36884. PubMed  Europe PubMed DOI  I
  288. Wilberding,J.A. and Castellino,F.J.
    Characterization of the murine coagulation factor X promoter
    Thromb Haemost84, 1031-1038. PubMed  Europe PubMed
    289. 1999
  289. [YEAR:5-11-1999]Camerer,E., Rottingen,J.A., Gjernes,E., Larsen,K., Skartlien,A.H., Iversen,J.G. and Prydz,H.
    Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene
    J Biol Chem274, 32225-32233. PubMed  Europe PubMed DOI
  290. [YEAR:9-9-1999]Ewing,W.R., Becker,M.R., Manetta,V.E., Davis,R.S., Pauls,H.W., Mason,H., Choi-Sledeski,Y.M., Green,D., Cha,D., Spada,A.P., Cheney,D.L., Mason,J.S., Maignan,S., Guilloteau,J.P., Brown,K., Colussi,D., Bentley,R., Bostwick,J., Kasiewski,C.J., Morgan,S.R., Leadley,R.J., Dunwiddie,C.T., Perrone,M.H. and Chu,V.
    Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa
    J Med Chem42, 3557-3571. PubMed  Europe PubMed DOI  I
  291. [YEAR:19-4-1999]Fevig,J.M., Buriak,J., Jr., Stouten,P.F., Knabb,R.M., Lam,G.N., Wong,P.C. and Wexler,R.R.
    Preparation of pyrrolidine and isoxazolidine benzamidines as potent inhibitors of coagulation factor Xa
    Bioorg Med Chem Lett9, 1195-1200. PubMed  Europe PubMed DOI  I
  292. Kaiser,B., Jeske,W., Walenga,J.M. and Fareed,J.
    Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood
    Blood Coagul Fibrinolysis10, 495-501. PubMed  Europe PubMed  I
  293. Leadley,R.J., Jr., Morgan,S.R., Bentley,R., Bostwick,J.S., Kasiewski,C.J., Heran,C., Chu,V., Brown,K., Moxey,P., Ewing,W.R., Pauls,H., Spada,A.P., Perrone,M.H. and Dunwiddie,C.T.
    Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa
    J Cardiovasc Pharmacol34, 791-799. PubMed  Europe PubMed DOI  I
  294. Sanderson,P.E.
    Small, noncovalent serine protease inhibitors
    Med Res Rev19, 179-197. PubMed  Europe PubMed DOI  V  I
    295. 1998
  295. [YEAR:1-10-1998]Heidtmann,H.H. and Kontermann,R.E.
    Cloning and recombinant expression of mouse coagulation factor X
    Thromb Res92, 33-41. PubMed  Europe PubMed DOI
  296. [YEAR:9-6-1998]Kamata,K., Kawamoto,H., Honma,T., Iwama,T. and Kim,S.H.
    Structural basis for chemical inhibition of human blood coagulation factor Xa
    Proc Natl Acad Sci U S A95, 6630-6635. PubMed  Europe PubMed DOI
  297. [YEAR:7-4-1998]Larson,P.J., Camire,R.M., Wong,D., Fasano,N.C., Monroe,D.M., Tracy,P.B. and High,K.A.
    Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles
    Biochemistry37, 5029-5038. PubMed  Europe PubMed DOI
  298. Liang,Z., Cooper,A., DeFord,M.E., Carmeliet,P., Collen,D., Castellino,F.J. and Rosen,E.D.
    Cloning and characterization of a cDNA encoding murine coagulation factor X
    Thromb Haemost80, 87-91. PubMed  Europe PubMed
  299. [YEAR:8-5-1998]Long,G.L., Lu,D., Xie,R.L. and Kalafatis,M.
    Human protein S cleavage and inactivation by coagulation factor Xa
    J Biol Chem273, 11521-11526. PubMed  Europe PubMed DOI
  300. [YEAR:9-1-1998]Nakata,M., Kanekura,S. and Maruyama,I.
    DX9065a, an Xa inhibitor, inhibits prothrombin-induced A549 lung adenocarcinoma cell proliferation
    Cancer Lett122, 127-133. PubMed  Europe PubMed DOI  I
  301. Salemink,I., Franssen,J., Willems,G.M., Hemker,H.C., Li,A., Wun,T.C. and Lindhout,T.
    Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity
    Thromb Haemost80, 273-280. PubMed  Europe PubMed
    302. 1997
  302. Bode,W., Brandstetter,H., Mather,T. and Stubbs,M.T.
    Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C
    Thromb Haemost78, 501-511. PubMed  Europe PubMed
  303. [YEAR:13-6-1997]Burgering,M.J., Orbons,L.P., van der Doelen,A., Mulders,J., Theunissen,H.J., Grootenhuis,P.D., Bode,W., Huber,R. and Stubbs,M.T.
    The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa
    J Mol Biol269, 395-407. PubMed  Europe PubMed DOI  S
  304. Butenas,S., DiLorenzo,M.E. and Mann,K.G.
    Ultrasensitive fluorogenic substrates for serine proteases
    Thromb Haemost78, 1193-1201. PubMed  Europe PubMed  A
  305. [YEAR:17-11-1997]Hopfner,K.P., Brandstetter,H., Karcher,A., Kopetzki,E., Huber,R., Engh,R.A. and Bode,W.
    Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants
    EMBO J16, 6626-6635. PubMed  Europe PubMed DOI
  306. Imamura,T., Potempa,J., Tanase,S. and Travis,J.
    Activation of blood coagulation factor X by arginine-specific cysteine proteinases (gingipain-Rs) from Porphyromonas gingivalis
    J Biol Chem272, 16062-16067. PubMed  Europe PubMed DOI
  307. James,H.L., Larson,P.J., Chao,Y.B., Yan,S.B. and Kim,D.J.
    Isolation and characterization of mouse coagulation factor X - Biophysical and enzymological properties
    Thromb Haemost78, 1049-1054. PubMed  Europe PubMed
  308. Katoh,T., Tamaki,M., Kikuchi,N., Teraoka,H., Nagata,K. and Yoshida,N.
    Mutations within the reactive-site region of human pancreatic secretory trypsin inhibitor confer alpha-thrombin and factor Xa inhibitory activities
    Biosci Biotechnol Biochem61, 389-391. PubMed  Europe PubMed DOI
  309. Krishnaswamy,S. and Betz,A.
    Exosites determine macromolecular substrate recognition by prothrombinase
    Biochemistry36, 12080-12086. PubMed  Europe PubMed DOI
  310. Rudolph,A.E., Mullane,M.P., Porche-Sorbet,R. and Miletich,J.P.
    Expression, purification, and characterization of recombinant human factor X
    Protein Expr Purif10, 373-378. PubMed  Europe PubMed DOI  E
    311. 1996
  311. [YEAR:22-11-1996]Brandstetter,H., Kuhne,A., Bode,W., Huber,R., von der Saal,W., Wirthensohn,K. and Engh,R.A.
    X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition
    J Biol Chem271, 29988-29992. PubMed  Europe PubMed DOI  S  I
  312. Edmunds,J.J. and Rapundalo,S.T.
    Chapter 6. Thrombin and factor Xa Inhibition
    Annu Rep Med Chem31, 51-60. DOI  I
  313. [YEAR:1-11-1996]Plescia,J. and Altieri,D.C.
    Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation
    Biochem J319, 873-879. PubMed  Europe PubMed
    314. 1995
  314. Lim-Wilby,M.S., Hallenga,K., De Maeyer,M., Lasters,I., Vlasuk,G.P. and Brunck,T.K.
    NMR structure determination of tick anticoagulant peptide (TAP)
    Protein Sci4, 178-186. PubMed  Europe PubMed DOI  S
  315. Matsuzaki,T., Umeyama,H. and Kikumoto,R.
    Mechanisms of the selective inhibition of thrombin, factor Xa, plasmin and trypsin
    Pharmacochem Libr23, 83-95. DOI  S  I
    316. 1994
  316. [YEAR:5-4-1994]Seymour,J.L., Lindquist,R.N., Dennis,M.S., Moffat,B., Yansura,D., Reilly,D., Wessinger,M.E. and Lazarus,R.A.
    Ecotin is a potent anticoagulant and reversible tight-binding inhibitor of factor Xa
    Biochemistry33, 3949-3958. PubMed  Europe PubMed
    317. 1993
  317. [YEAR:5-8-1993]Padmanabhan,K., Padmanabhan,K.P., Tulinsky,A., Park,C.H., Bode,W., Huber,R., Blankenship,D.T., Cardin,A.D. and Kisiel,W.
    Structure of human des(1-45) factor Xa at 2.2 A resolution
    J Mol Biol232, 947-966. PubMed  Europe PubMed DOI  S
    318. 1991
  318. Suzuki,H., Harada,A., Hayashi,Y., Wada,K., Asaka,J., Gotoh,B., Ogasawara,T. and Nagai,Y.
    Primary structure of the virus activating protease from chick embryo. Its identity with the blood clotting factor Xa
    FEBS Lett283, 281-285. PubMed  Europe PubMed DOI
    319. 1990
  319. [YEAR:15-10-1990]Neeper,M.P., Waxman,L., Smith,D.E., Schulman,C.A., Sardana,M., Ellis,R.W., Schaffer,L.W., Siegl,P.K. and Vlasuk,G.P.
    Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa
    J Biol Chem265, 17746-17752. PubMed  Europe PubMed
    320. 1987
  320. [YEAR:5-3-1987]Krishnaswamy,S., Church,W.R., Nesheim,M.E. and Mann,K.G.
    Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism
    J Biol Chem262, 3291-3299. PubMed  Europe PubMed
    321. 1984
  321. Cho,K., Tanaka,T., Cook,R.R., Kisiel,W., Fujikawa,K., Kurachi,K. and Powers,J.C.
    Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates
    Biochemistry23, 644-650. PubMed  Europe PubMed
  322. [YEAR:10-6-1984]Gitel,S.N., Medina,V.M. and Wessler,S.
    Inhibition of human activated factor X by antithrombin III and alpha 1-proteinase inhibitor in human plasma
    J Biol Chem259, 6890-6895. PubMed  Europe PubMed
  323. [YEAR:15-5-1984]Jesty,J., Morrison,S.A. and Harpel,P.C.
    Measurement of human activated factor X-antithrombin complex by an enzyme-linked differential-antibody immunosorbent assay
    Anal Biochem139, 158-167. PubMed  Europe PubMed
  324. [YEAR:1-6-1984]Lijnen,H.R., Uytterhoeven,M. and Collen,D.
    Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones
    Thromb Res34, 431-437. PubMed  Europe PubMed  I
    325. 1983
  325. [YEAR:31-10-1983]Choay,J., Petitou,M., Lormeau,J.C., Sinay,P., Casu,B. and Gatti,G.
    Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity
    Biochem Biophys Res Commun116, 492-499. PubMed  Europe PubMed
  326. Fuchs,H.E. and Pizzo,S.V.
    Regulation of factor Xa in vitro in human and mouse plasma and in vivo in mouse. Role of the endothelium and plasma proteinase inhibitors
    J Clin Invest72, 2041-2049. PubMed  Europe PubMed DOI
  327. McMullen,B.A., Fujikawa,K., Kisiel,W., Sasagawa,T., Howald,W.N., Kwa,E.Y. and Weinstein,B.
    Complete amino acid sequence of the light chain of human blood coagulation factor X: evidence for identification of residue 63 as beta-hydroxyaspartic acid
    Biochemistry22, 2875-2884. PubMed  Europe PubMed
    328. 1982
  328. [YEAR:4-2-1982]Ellis,V., Scully,M., MacGregor,I. and Kakkar,V.
    Inhibition of human factor Xa by various plasma protease inhibitors
    Biochim Biophys Acta701, 24-31. PubMed  Europe PubMed
    329. 1981
  329. McRae,B.J., Kurachi,K., Heimark,R.L., Fujikawa,K., Davie,E.W. and Powers,J.C.
    Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates
    Biochemistry20, 7196-7206. PubMed  Europe PubMed
    330. 1980
  330. Enfield,D.L., Ericsson,L.H., Fujikawa,K., Walsh,K.A., Neurath,H. and Titani,K.
    Amino acid sequence of the light chain of bovine factor X1 (Stuart factor)
    Biochemistry19, 659-667. PubMed  Europe PubMed
  331. Jackson,C.M. and Nemerson,Y.
    Blood coagulation
    Annu Rev Biochem49, 765-811. PubMed  Europe PubMed DOI
  332. Robison,D.J., Furie,B., Furie,B.C. and Bing,D.H.
    Active site of bovine factor Xa. Characterization using substituted benzamidines as competitive inhibitors and affinity-labeling reagents
    J Biol Chem255, 2014-2021. PubMed  Europe PubMed  I
    333. 1979
  333. Davie,E.W., Fujikawa,K., Kurachi,K. and Kisiel,W.
    The role of serine proteases in the blood coagulation cascade
    Adv Enzymol Relat Areas Mol Biol48, 277-318. PubMed  Europe PubMed
    334. 1977
  334. Aurell,L., Friberger,P., Karlsson,G. and Claeson,G.
    A new sensitive and highly specific chromogenic peptide substrate for factor Xa
    Thromb Res11, 595-609. PubMed  Europe PubMed
  335. Morita,T., Kato,H., Iwanaga,S., Takada,K., Kimura,T. and Sakakibara,S.
    New fluorogenic substrates for alpha-thrombin, factor Xa, kallikreins, and urokinase
    J Biochem82, 1495-1498. PubMed  Europe PubMed  A
  336. Suttie,J.W. and Jackson,C.M.
    Prothrombin structure, activation, and biosynthesis
    Physiol Rev57, 1-70. PubMed  Europe PubMed
    337. 1976
  337. Fujikawa,K. and Davie,E.W.
    Bovine factor X (Stuart factor)
    Methods Enzymol45, 89-95. PubMed  Europe PubMed DOI  V
  338. Furie,B. and Furie,B.C.
    Spectral changes in bovine factor X associated with activation by the venom coagulant protein of Vipera russelli
    J Biol Chem251, 6807-6814. PubMed  Europe PubMed
  339. Jesty,J. and Nemerson,Y.
    The activation of bovine coagulation factor X
    Methods Enzymol45, 95-107. PubMed  Europe PubMed DOI  V
  340. Sturzebecher,J., Markwardt,F. and Walsmann,P.
    Synthetic inhibitors of serine proteinases. XIV. Inhibition of factor Xa by derivatives of benzamidine
    Thromb Res9, 637-646. PubMed  Europe PubMed  I
    341. 1973
  341. Jameson,G.W., Roberts,D.V., Adams,R.W., Kyle,W.S. and Elmore,D.T.
    Determination of the operational molarity of solutions of bovine alpha-chymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration
    Biochem J131, 107-117. PubMed  Europe PubMed  I
    342. 1972
  342. Jackson,C.M.
    Characterization of two glycoprotein variants of bovine factor X and demonstration that the factor X zymogen contains two polypeptide chains
    Biochemistry11, 4873-4882. PubMed  Europe PubMed
  343. [YEAR:19-12-1972]Titani,K., Hermodson,M.A., Fujikawa,K., Ericsson,L.H., Walsh,K.A., Neurath,H. and Davie,E.W.
    Bovine factor X1a (activated Stuart factor). Evidence of homology with mammalian serine proteases
    Biochemistry11, 4899-4903. PubMed  Europe PubMed
    344. 1962
  344. Esnouf,M.P. and Williams,W.J.
    The isolation and purification of a bovine-plasma protein which is a substrate for the coagulant fraction of Russell's-viper venom
    Biochem J84, 62-71. PubMed  Europe PubMed
    345. 1957
  345. Hougie,C., Barrow,E.M. and Graham,J.B.
    Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called stable factor (SPCA, proconvertin, factor VII) deficiency
    J Clin Invest36, 485-496. PubMed  Europe PubMed DOI  M

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2025 EBI
Terms of use